



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/87, C12P 19/34	A1	(11) International Publication Number: WO 98/11214
		(43) International Publication Date: 19 March 1998 (19.03.98)

(21) International Application Number: PCT/IB97/01217

(22) International Filing Date: 11 September 1997 (11.09.97)

(30) Priority Data:
60/025,929 11 September 1996 (11.09.96) US(71) Applicants: THOMAS JEFFERSON UNIVERSITY [US/US];
1020 Locust Street, Philadelphia, PA 19107-6799 (US).
CORNELL RESEARCH FOUNDATION, INC. [US/US];
Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).(72) Inventors: HOLLOMAN, William, K.; 2025 Hunterbrook
Road, Yorktown Heights, NY 10598 (US). RICE, Michael,
C.; 258 South State Street, Newtown, PA 18940 (US).
SMITH, Sheryl, T.; 754 Old Railroad Avenue, Bryn Mawr,
PA 19010 (US). SHU, Zhigang; 629 Hummingbird Lane,
Bensalem, PA 19020 (US). KMIEC, Eric, B.; 1570 Reaper
Court, Yardley, PA 19067 (US).(74) Agents: HANSBURG, Daniel; Kimeragen, Inc., 300 Pheasant
Run, Newtown, PA 18940 (US) et al.(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY,
CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP,
KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD,
SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: MAMMALIAN AND HUMAN REC2

(57) Abstract

The invention concerns mammalian recombinase genes (REC2) and their promoters. Over expression of REC2 in a cell is found to facilitate homologous recombination, particularly homologous recombination using a DNA/RNA chimeric oligonucleotide and to sensitize a cell to the apoptotic effects of irradiation. The REC2 promoter, in combination with a strong enhancer, e.g., a SV40 enhancer, was found to be a strong promoter following irradiation of the cells. A radiation inducible promoter can be used to sensitize a cell to radiation treatment by operably linking the radiation inducible promoter to a gene whose expression converts a prodrug to a drug such as a herpes thymidine kinase gene.

ATTORNEY DOCKET NUMBER: 7991-086-99

SERIAL NUMBER: 09/685,403

REFERENCE: BR

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/87, C12P 19/34	A1	(11) International Publication Number: WO 98/11214
		(43) International Publication Date: 19 March 1998 (19.03.98)

(21) International Application Number: PCT/IB97/01217

(22) International Filing Date: 11 September 1997 (11.09.97)

(30) Priority Data:
60/025,929 11 September 1996 (11.09.96) US(71) Applicants: THOMAS JEFFERSON UNIVERSITY [US/US];
1020 Locust Street, Philadelphia, PA 19107-6799 (US).
CORNELL RESEARCH FOUNDATION, INC. [US/US];
Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).(72) Inventors: HOLLOMAN, William, K.; 2025 Hunterbrook
Road, Yorktown Heights, NY 10598 (US). RICE, Michael,
C.; 258 South State Street, Newtown, PA 18940 (US).
SMITH, Sheryl, T.; 754 Old Railroad Avenue, Bryn Mawr,
PA 19010 (US). SHU, Zhigang; 629 Hummingbird Lane,
Bensalem, PA 19020 (US). KMIEC, Eric, B.; 1570 Reaper
Court, Yardley, PA 19067 (US).(74) Agents: HANSBURG, Daniel; Kimeragen, Inc., 300 Pheasant
Run, Newtown, PA 18940 (US) et al.(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY,
CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KG, KP,
KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD,
SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG).**Published***With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: MAMMALIAN AND HUMAN REC2

(57) Abstract

The invention concerns mammalian recombinase genes (REC2) and their promoters. Over expression of REC2 in a cell is found to facilitate homologous recombination, particularly homologous recombination using a DNA/RNA chimeric oligonucleotide and to sensitize a cell to the apoptotic effects of irradiation. The REC2 promoter, in combination with a strong enhancer, e.g., a SV40 enhancer, was found to be a strong promoter following irradiation of the cells. A radiation inducible promoter can be used to sensitize a cell to radiation treatment by operably linking the radiation inducible promoter to a gene whose expression converts a prodrug to a drug such as a herpes thymidine kinase gene.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

MAMMALIAN AND HUMAN REC2

This application claims benefit of the priority of U.S. provisional application Serial No. 60/025,929, filed September 11, 1996.

1. FIELD OF THE INVENTION

The present invention concerns the field of molecular genetics and medicine. Particularly, it concerns genes encoding a protein that is involved in homologous recombination and the repair of damaged genomic DNA in mammalian cells. Specifically the invention concerns the gene encoding a mammalian ATP-dependent homologous pairing protein; methods of using the gene to effect gene therapy; methods of using the gene and fragments of the gene to classify a mammalian tissue for medical purposes; and transgenic mice having had one or both alleles of the gene made inoperative. More specifically, the gene of the present invention is the human and murine homologs of the gene termed *REC2* previously isolated from the fungus *Ustilago maydis*.

2. BACKGROUND OF THE INVENTION

During the life of every organism the DNA of its cells is constantly subjected to chemical and physical events that cause alterations in its structure, i.e., potential mutations. These potential mutations are recognized by DNA repair enzymes found in the cell because of the mismatch between the strands of the DNA. To prevent the deleterious effects that would occur if these potential mutations became fixed, all organisms have a variety of mechanisms to repair DNA mismatches. In addition, higher animals have evolved mechanisms whereby cells having highly damaged DNA, undergo a process of programmed death ("apoptosis").

The association between defects in the DNA mismatch repair and apoptosis inducing pathways and the development, progression and response to treatment of oncologic disease is widely recognized, if incompletely understood, by medical scientists. Chung, D.C. & Rustgi, A.K., 1995, *Gastroenterology* 109:1685-99; Lowe, S.W., et al., 1994, *Science* 266:807-10. Therefore, there is a continuing need to identify and clone the genes that encode proteins involved in DNA repair and DNA mismatch monitoring.

Studies with bacteria, fungi and yeast have identified three genetically defined groups of genes involved in mismatch repair processes. The groups are termed, respectively, excision repair group, the error prone repair group and recombination repair group. Mutants in a gene of each group results in a characteristic phenotype. Mutants in the recombination repair group in yeast result in a phenotype having extreme sensitivity to ionizing radiation, a sporulation deficiency, and decreased or absent mitotic recombination. Petes, T.D., et al., 1991, in Broach, J.R., et al., eds., THE MOLECULAR BIOLOGY OF THE YEAST *SACCHAROMYCES*, pp. 407-522 (Cold Spring Harbor Press, 1991).

Several phylogenetically related genes have been identified in the recombination repair group: *recA*, in *E. Coli*, Radding, C.M., 1989, Biochim. Biophys. Acta 1008:131-145; *RAD51* in *S. cerevisiae*, Shinohara, A., 1992, Cell 69:457-470, Aboussekhra, A.R., et al., 1992, Mol. Cell. Biol. 12:3224-3234, Basile, G., et al., 1992, Mol. Cell. Biol. 12:3235-3246; *RAD57* in *S. cerevisiae*, Gene 105:139-140; *REC2* in *U. maydis*, Bauchwitz, R., & Holloman, W.K., 1990, Gene 96:285-288, Rubin, B.P., et al., 1994, Mol. Cell. Biol. 14:6287-6296. A third *S. cerevisiae* gene *DMC1*, is related to *recA*, although mutants of *DMC1* show defects in cell-cycle progression, recombination and meiosis, but not in recombination repair.

The phenotype of *REC2* defective *U. maydis* mutants is characterized by extreme sensitivity to ionizing radiation, defective mitotic recombination and interplasmid recombination, and an inability to complete meiosis. Holliday, R., 1967, Mutational Research 4:275-288. UmREC2, the *REC2* gene product of *U. maydis*, has been extensively studied. It is a 781 amino acid ATPase that, in the presence of ATP, catalyzes the pairing of homologous DNA strands in a wide variety of circumstances, e.g., UmREC2 catalyzes the formation of duplex DNA from denatured strands, strand exchange between duplex and single stranded homologous DNA and the formation of a nuclease resistant complex between identical strands. Kmiec, E.B., et al., 1994, Mol. Cell. Biol. 14:7163-7172. UmREC2 is unique in that it is the only eukaryotic ATPase that forms homolog pairs, an activity it shares with the *E. coli* enzyme *recA*.

U.S. patent application, Serial No. 08/373,134, filed January 17, 1995, by W.K. Holloman and E.B. Kmiec discloses *REC2* from *U. maydis*, methods of producing recombinant UmREC2 and methods of its use. Prior to the date of the present invention a

fragment of human *REC2* cDNA was available from the IMAGE consortium, Lawrence Livermore National Laboratories, as plasmid p153195. Approximately 400 bp of the sequence of p153195 had been made publicly available on dbEST database.

The scientific publication entitled: ISOLATION OF HUMAN AND MOUSE GENES BASED ON HOMOLGY TO *REC2*, July 1997, Proc. Natl. Acad. Sci. **94**, 7417-7422 by Michael C. Rice et al., discloses the sequences of murine and human *Rec2*, of the human *REC2* cDNA. and discloses that irradiation increases the level of *hsREC2* transcripts in primary human foreskin fibroblasts.

3. SUMMARY OF THE INVENTION

The invention provides nucleic acids encoding mammalian ATP-dependent homologous pairing proteins (a "mammalian recombinase") particularly, the human and murine ATP-dependent homologous pairing protein (*hsREC2* and *muREC2*, respectively). The invention additionally provides DNA clones containing a copy of the mRNA encoding a mammalian recombinase (an "mREC cDNA") and DNA clones containing a copy of the genomic DNA containing an mREC gene or fragments thereof. In further embodiments, the invention concerns a nucleic acid comprising an mREC cDNA linked to a heterologous promoter, i.e., a promoter other than a mammalian recombinase promoter, so that a mammalian recombinase can be expressed or over-expressed in insect and mammalian cells and in bacteria. In one embodiment, the heterologous promoter is the polyhedrin promoter from the baculovirus *Autographica californica* and the invention provides for an isolated and purified mammalian recombinase, particularly isolated and purified *hsREC2*.

The invention provides several utilities of said nucleic acids and isolated and purified proteins. In the area of gene therapy and the construction of transgenic animals, the invention provides a method of enhancing homologous recombination between an exogenous nucleic acid and the genome of a cell by introducing a plasmid that expresses an mammalian recombinase into the cell, which method can be used to repair a genetic defect and thereby cure a genetic disease. Alternatively, for the construction of transgenic animals the invention provides a method of enhancing homologous recombination between an exogenous nucleic acid and the genome of a cell by introducing purified

mammalian recombinase into the cell. Alternatively, the invention provides for the construction of a transgenic animal, such as a mouse, having a transgenic mammalian recombinase gene operably linked to a strong promoter so that the recombinase is over expressed in some or all tissues. Such transgenic animals are highly adapted to undergo homologous recombination.

The invention additionally provides two methods of classifying a sample of human tissue for diagnosis and prognosis: by determining whether the cells of the sample contains two, one or no copies of *hsREC2*; and by determining whether the copies of *hsREC2* that said cells contain are mutated. For the purpose of diagnosis and classification of tissue samples the invention, firstly, provides paired oligonucleotides that are suitable for the PCR amplification of fragments of *hsREC2* and, secondly, identifies a microsatellite DNA sequence, D14S258, that is closely linked to *hsREC2*.

The invention further provides a transgenic mouse having one or both alleles of *muREC2* interrupted and thereby inactivated. The resultant transgenic animals, termed heterozygous and homozygous *REC2*-knock out mice, respectively, are susceptible to tumorigenesis by chemical carcinogens. *REC2*-knock-out mice can be used to determine whether there is a significant risk of carcinogenesis associated with a chemical or a process of interest. The reduced level or absence of *muREC2* makes *REC2*-knock-out mice a more sensitive test animal than wild-type.

The invention further provides a method of sensitizing target cells to DNA damage, such as from γ - or UV irradiation or from cytotoxic agents commonly used in oncologic therapy, which comprises causing the expression of high levels of recombinase in the target cell. The expression of such levels causes the cells to more readily undergo apoptosis in response to DNA damage. The invention yet further provides the *REC2* promoter a mammalian promoter that is inducible by irradiation or other DNA damaging agents.

4. BRIEF DESCRIPTION OF THE FIGURES

Figures 1A-1G. Figures 1A and 1B show the derived amino acid sequence of *hsREC2* (SEQ ID NO:1), and Figures 1C and 1D show the nucleic acid sequences of the *hsREC2* cDNA coding strand (SEQ ID NO:2). Figures 1E and 1F show the derived amino

acid sequence of muREC2 (SEQ ID NO:3), and Figure 1G shows the nucleic acid sequences of the *hsREC2* cDNA coding strand (SEQ ID NO:4).

Figure 2A-2D. Figure 2A is an annotated amino acid sequence of *hsREC2*. Specifically noted are the nuclear localization sequence ("NLS"), A Box and B Box motif sequences, DNA binding sequence and a src-type phosphorylation site ("P"). Figure 2B is a cartoon of the annotated sequence, showing in particular the region 80-200 is most closely related to *recA*. Figures 2C-2D show the sequence homology between *hsREC2* and *Ustilago maydis* REC2. The region of greatest similarity, 43% homology, is in bold.

Figure 3. Figure 3 shows the DNA reannealing as a function of added baculovirus-produced hexahistidylHsREC2.

Figure 4. Figure 4 is a gel shift assay showing that binding of a *hsREC2*-thioredoxin fusion protein to ssDNA is ATP or γ -S-ATP dependent.

Figure 5A-5B. Figure 5A shows the frequency of repair of the Sickle Cell Disease mutation, as a function of added β^S - β^A chimeric repair vector (SC1), in the β -globin genes in a population of EBV-transformed human lymphoblasts in the presence or absence of the *hsREC2* expression vector pcHsREC2, pcDNA3 or pcCAT control plasmids or SC1 alone. Figure 5B shows the sequences of SC1, β^S and β^A in the region of the Sickle Cell mutation. Lower case (a, c, g, and u) indicates 2'-OMe nucleotides.

Figure 6. Figure 6 shows the reannealing of a 123 nt DNA fragment is catalyzed by GST/REC2 fusion protein.

Figures 7A-7F. Figures 7A-7C show the sequence of the *hsREC2* promoters and Figures 7D-7F show the sequence of the *muREC2* promoters. The locations of sequences homologous to the sequences of known cis-acting radiation responsive elements in yeast are underlined and the corresponding yeast gene is indicated.

Figures 8A-8H. Figures 8A-8H show FACS histograms of RNase treated, propidium iodide stained, CHO cells that have been transfected with either an *hsREC2* expressing plasmid (15C8) or an irrelevant control plasmid (Neo). The DNA content of the cells is displayed in the horizontal axis. The histograms are of unirradiated cells (8A, 8E) or of cells that are 24, 48 or 72 hours status post exposure to 15 J/m^2 UV irradiation (8B-8D, 8F-8H). The comparison shows that the expression of *hsREC2* increases the fraction of irradiated cells having less than the diploid DNA content, which is indicative of

of apoptosis.

5. DETAILED DESCRIPTION OF THE INVENTION

As used herein, genes are *italicized*, e.g., *hsREC2*, while the corresponding protein is in normal typeface.

5.1 *hsREC2* AND THE STRUCTURE OF ITS PRODUCT *hsREC2*

The results of efforts to obtain *hsREC2* cDNA by hybridization under non-stringent conditions with *UmREC2* probes were unsatisfactory. Efforts were made to isolate a fragment of *hsREC2* by PCR amplification using primers that encode pentapeptides based on the *UmREC2* sequence. A mixture of four forward primers encoding residues 256-260 of *UmREC2*, GKTQM (SEQ ID NO:7), was constructed using inosine as the third base for the gly and thr codons and having a 5' noncoding GC dinucleotide, i.e., 5'-GC GGI AA(G/A) ACI CA(G/A) ATG-3'. A mixture of eight reverse primers complementary to the sequences that can encode residues 330-334 of *UmREC2*, YITSG, was synthesized, using inosine in the same way as the forward primers, i.e., 5'-CC ICC G(C/G)(T/A)¹ IGT IAT (A/G)TA-3'. The primers were used to amplify fragments of human genomic and cDNA libraries using the Expand™ system (Boehringer) coupled with two rounds of reamplification. After reamplification the fragments were cloned in pCRII (Invitrogen). Ten different mixtures of primers encoding a total of nine different pentapeptides were used and a total of about 60 fragments were sequenced. One 110 bp fragment from a human kidney cDNA library, *hsr110*, had statistically significant homology with *UmREC2*.

A computer search of the database dbEST was performed to find clones of cDNAs encoding proteins that have significant homologies with *UmREC2* and *hsr110*. The plasmid p153195 was identified as having significant homology with *UmREC2* and which contained *hsr110*. In one segment of 44 residues of *UmREC2* and *hsREC2*, there was 43% homology between *UmREC2* and *hsREC2*, i.e., 19 of the 44 residues of each sequence were identical. Additionally, there were 8 conservative substitutions. This

¹ Only two of the four combinations are complementary to ser codons, however, they are complementary to the ser codons most often used in humans.

region of high homology corresponds to residues 84-127 of *hsREC2* and residues 226-270 of *UmREC2*. See Figures 2C-2D. Residues 226-270 of *UmREC2* is the portion of *UmREC2* that is most highly conserved when compared to *recA* and related members of the recombination repair group; cf. residues 40-95 of *recA*, 95-13 of *DMC1*, residues 100-144 of *RAD51*, and residues 160-204 of *RAD51*. See, e.g., Figure 2, Rubin et al., 1994 *supra*.

That clone p153195 lacked the 5' end of *hsREC2* was determined by the absence of an inframe start codon. The 5' end of *hsREC2* cDNA was obtained by PCR amplification of a cDNA library using a forward primer from the cloning vector and nested reverse primers based on p153195. An overlap of about 100 bp was identified which contained a unique restriction site that was used to reconstruct the full length *hsREC2* cDNA. The sequences of the reconstructed *hsREC2* cDNA are given in Figures 1A-1B and the derived sequence of *hsREC2* are given in Figures 1C-1D. The *hsREC2* cDNA encodes a protein of 350 amino acids, SEQ ID NO:1. The sequence of the *hsREC2* cDNA and its complement are SEQ ID NO: 2 and No: 3, respectively. The 5' boundary of p153195 was about nt 280 of SEQ ID NO: 2.

Comparisons of the *hsREC2* sequence with the *UmREC2* sequence reveals statistically significant, but distant homologies ($p = 2.8 \times 10^{-5}$). A similar level of homology is found between *hsREC2* and the yeast protein *DMC1*.

An expression vector containing the complete *hsREC2* cDNA under control of a strong promoter, for example, the cytomegalovirus promoter (*pcHsREC2*), can be constructed for over-expression of *hsREC2* in transfected eukaryotic cells. For the production of purified *hsREC2* a vector suitable for the expression of the *hsREC2* under control of the baculovirus polyhedrin promoter can be constructed. It is preferred to construct a vector that synthesizes a *REC2* fusion protein consisting of a protein or peptide that aids in the purification of the product, such as a hexahistidyl peptide or glutathione S-transferase. Figures 1E-1F and 1G show the derived amino acid and nucleic acid sequences of the murine *REC2* (*muREC2*) cDNA.

5.2 HOMOLOGS OF *hsREC2*

The present invention encompasses mammalian homologs of *hsREC2*. Nucleic

acids encoding the REC2 from any mammalian species can be identified and isolated by techniques, routine to those skilled in the art, using the sequence information of Figures 1A-1D and/or the *hsREC2* cDNA clone. Such routine techniques include use of the *hsREC2* cDNA or fragments thereof to probe cDNA and genomic libraries from other mammalian species and use of the sequence data to construct primers for PCR amplification of fragments of mammalian REC2 cDNA. The cloning of *hsREC2* and *muREC2* genomic DNA (gDNA) is described below.

High levels of transcripts of *hsREC2* can be found in heart and skeletal muscle, lung, pancreas, spleen and thymus, and placenta. Moderate or low levels of *hsREC* transcripts are found in liver, kidney, brain and testes. Thus, the source of mRNA to construct cDNA libraries for obtaining mammalian REC2 clones is not critical. The sequence of residues 83-127, which corresponds to amino acids 226-270 of UmREC2, is particularly highly conserved and is, therefore, useful in identifying mammalian REC2 homologs.

Mammalian homologs of *hsREC2* can be identified by the presence of an amino acid sequence identity of greater than 80% and preferably greater than 90% compared to *hsREC2* in the highly conserved portions of the gene, i.e., the portion homologous to residues 83-127 of *hsREC2*. In a preferred embodiment the mammalian recombinase gene shares greater than 80% sequence identity with *hsREC2* gene within the about 130 bp segment that encodes the residues homologous with residues 83-127 of *hsREC2*. Such mammalian homologs of *hsREC2* will also have the above-noted activities of catalyzing DNA reannealing, ATPase activity and ATP-dependent ssDNA binding activity.

As used herein, a protein having each of these three activities is termed an ATP-dependent homologous pairing protein (a "mammalian recombinase"). A mammalian recombinase having greater than an 80% sequence identity with *hsREC2* is termed an "mREC2." Based on the extensive studies of bacterial and yeast homologous recombination proteins, those skilled in the art anticipate that all mammalian recombinases will have greater than 80% amino acid sequence identity with *hsREC2*, i.e., be an mREC2.

The invention further encompasses fusion proteins comprising a mammalian REC2 protein or fragment thereof, wherein the REC2 fragment displays at least one and

preferably each of the three above-noted activities to substantially the same extent as the native REC2. Those skilled in the art appreciate that the recombinant production and purification of mammalian proteins in bacterial and insect cell based expression systems is facilitated by the construction of fusion proteins that contain the protein of interest and a second protein that stabilizes the resultant fusion protein and facilitates its purification. Non-limiting examples of fusion proteins include hexahistidyl, Glutathione-S-transferase and thioredoxin fused to the amino terminus of REC2.

In one embodiment, the invention is a composition containing an isolated and purified protein, which is an ATP-dependent homologous pairing protein, i.e., is an ATP-dependent catalyst of DNA reannealing, is an ATPase, and binds ssDNA in the presence of ATP or γ -S-ATP, and which protein comprises a polypeptide of at least 115 amino acids which is substantially identical to a polypeptide found in a mammalian ATP-dependent homologous pairing enzyme. More preferably the isolated and purified protein comprises a polypeptide that is substantially identical to residues 80-200 of hsREC2. In a further embodiment, the isolated and purified protein of the invention comprises the polypeptide which is residues 2-350 of SEQ ID NO:1. As used herein, substantially identical means identical or having at most one conservative substitution per 20 amino acids. As used herein a human protein is an isolated and purified human protein if the composition containing the protein is substantially free of all other normally intracellular human proteins but a defined set of individually identified human proteins; similarly an isolated and purified mammalian protein is free of all other normally intracellular mammalian proteins except for a defined set of individually identified mammalian proteins. As used herein, "a composition which comprises a defined protein substantially free of a named material" means that the weight of the named material in the composition is less than 5% of the weight of the protein in the composition.

The invention further provides an isolated and purified nucleic acid derived from a mammalian species, i.e., derived from a cDNA or gDNA clone, that encodes a protein or fusion protein, having a sequence, which comprises the sequence of a mammalian ATP-dependent homologous pairing protein or a substantially identical sequence. As used herein, an isolated and purified nucleic acid is a nucleic acid isolated and purified free of nucleic acids encoding other mammalian proteins or fragments thereof. As used herein,

the sequence of a mammalian ATP-dependent homologous pairing protein means the sequence of a naturally occurring, i.e., wild-type ATP-dependent homologous pairing protein found in a mammal, or of any mutants of wild-type mammalian ATP-dependent homologous pairing protein. In preferred embodiments the nucleic acid of the invention encodes a protein that is greater than 80% sequence identical, or alternatively, more than 90% sequence identical to hsREC2. Those skilled in the art appreciate that the N-terminal and C-terminal one, two or three amino acids can be substituted or deleted without effect and, as used herein, are not considered a part of the sequence unless so specified. Those skilled in the art further appreciate that the insertion or deletion of one to four consecutive amino acids during the evolution of homologous proteins is common. Therefore, in the definition of sequence identity between proteins encompasses the introduction of as many as four, one to four residue gaps in one or both sequences to maximize identity.

The isolated and purified nucleic acids of the invention encompass not only cDNA and gDNA clones of mammalian genes encoding a mammalian ATP-dependent homologous pairing protein, but also nucleic acids derived from said cDNA and gDNA clones by site directed mutagenesis. By use of routine PCR techniques, those skilled in the art can make specific, predetermined changes in the sequence of a DNA. Site directed mutagenesis may be conducted by any method. The method of Ho, S.N., et al., GENE 77:51-59 (herewith incorporated by reference in its entirety), is suitable. According to the method of Ho, overlapping, mutated genome fragments are synthesized in two separate PCR reactions. Of the four primers are used in the two reactions, two are complementary to each other and introduce the desired mutation. The PCR reactions are performed so that the 3' end of the sense strand of one product is complementary to the 3' end of antisense strand of the other. The two PCR products are denatured, mixed and reannealed. The overlapping partial duplex molecules are then extended form a full length dsDNA, amplified in a third PCR reaction, the product isolated and inserted by conventional recombinant techniques into the parent gene. See, also, Liang, Q., et al., 1994, PCR Methods & Applic. 4:269-74; Weiner, M.P. & Costa, G.L., 1994, PCR Methods & Applic. 4:S131-136; Barrettino, D., et al., 1994, Nucleic Acids Research 22:541; Stemmer, W.P., et al., 1992, Biotechniques 13:214-220. By multiple

applications of such techniques any desired modifications in the sequence of a cloned DNA can be introduced. Thus, the nucleic acids of the invention are not limited to isolated and purified nucleic acids having naturally occurring sequences, but also include nucleic acids encoding a ATP-dependent homologous pairing protein having substantially the same sequence as a naturally occurring mammalian recombinase.

The compositions of the invention further include compositions comprising not only mammalian recombinases isolated and purified free of mammalian proteins, but also compositions comprising any isolated and purified ATP-dependent homologous pairing protein having substantially the same sequence as a naturally occurring mammalian recombinase.

The hsREC2 sequence contains several sequences that have been identified with specific functions in other proteins. Figure 2A shows the sequence of hsREC2 and indicates the locations of nuclear localization sequence, four sequences associated with recA, namely A box, B box, a src-like phosphorylation site and a DNA binding site. Those skilled in the art will appreciate that, as was found for UmREC2, not all portions of a mREC2 protein are essential for the *in vitro* activities that characterize ATP-dependent homologous binding proteins. However, the region of about 120 amino acids from about residue 80 to residue 200, which is recA-like, is essential for these activities.

5.3 THE USE OF mREC2 AND mREC2 ENCODING GENES TO EFFECT HOMOLOGOUS RECOMBINATION BETWEEN THE GENOME OF A CELL AND AN EXOGENOUS NUCLEIC ACID

In one embodiment of the invention, a plasmid that expresses an mREC2 is used to increase the rate of homologous recombination between an exogenous nucleic acid and the genome of a cell. In one embodiment, the exogenous nucleic acid is a chimeric repair vector (CRV), which is an oligonucleotide having mixed ribo- and deoxyribonucleotides. The structure of CRV are disclosed in U.S. patent applications Serial No. 08/353,657, filed December 4, 1994, and Serial No. 08/664,487, filed June 17, 1996, which are hereby incorporated by reference in its entirety. U.S. application Serial No. 08/640,517, entitled "Methods and Compounds for Curing Diseases Caused by Mutations," filed May 1, 1996, by E.B. Kmiec, A. Cole-Strauss and K. Yoon, (the '517 Application), which is hereby incorporated by reference in its entirety, describes the use

of CRV to repair mutations that cause diseases. Particularly, the '517 Application concerns the repair of mutations that affect hematopoietic cells such as the mutation in β -globin that causes Sickle Cell Disease.

According to the present invention, the cell having a disease-causing mutation to be repaired (the target cell) is removed from the subject. The target cells are then transfected with a nucleic acid having a promoter operably linked to a nucleic acid encoding a mREC2 (an mREC2 expression vector) such that a mammalian ATP-dependent homologous pairing protein is over-expressed in the target cell. For most types of human cells, the immediate early promoter from cytomegalovirus is suitable. Because the persistent over-expression of a mammalian ATP-dependent homologous pairing protein can effect the growth and differentiation of the target cell, the mREC2 expression vector should be incapable of replication in the target cell. The mREC2 expression vector can be introduced into the target cell by any technique known to those in the field or to be developed. Liposomal compositions such as LIPOFECTIN^(TM) and DOTAP^(TM) are suitable.

After transfection with the mREC2 expression vector, the target cells are cultured for twenty four hours and then a CRV designed to repair the disease causing mutation is introduced into the target cells, according to the methods of the '517 Application, and repaired target cells are then reimplanted into the subject. Alternatively, the repaired target cells can be frozen and reimplanted at a clinically opportune time.

Figure 5A shows the results of the use of an mREC2 expression vector to enhance the effectiveness of a CRV that repairs the mutation that causes Sickle Cell Disease in a human EB-transformed lymphoblastoid cell line. These data show that at a concentration of CRV of about 100 ng/ml, the pretreatment of the target cells with the mREC2 expression vector pcHsREC2, labelled "pchREC2" in Figure 5A, caused an about 5 fold increase, from 12% to 65%, in the percent of repaired copies of β -globin. At 250 ng/ml, over 80% of the copies of β -globin were repaired. At higher concentrations of CRV, the differences between pcHsREC2 treated target cells and control target cells become less marked.

The present invention is exemplified by the use of a non-replicating episome to introduce an mREC2 cDNA gene (*hsREC2*), operably linked to a cytomegalovirus (CMV) promoter, into the target cell and to transiently express mREC2. Alternative embodiments

of the invention can be produced by introducing the copy of a genomic gene, which can be linked to the homologous mREC2 promoter or, alternatively, modified so that the homologous promoter is replaced by a CMV or other heterologous promoter. Further variants that can be used to increase homologous recombination in different situations include linkage of either mREC2 cDNA or gDNA to tissue specific promoters such as a CD4, immunoglobulin, insulin or globin promoter. By use of tissue specific promoters, transgenic animals, particularly mice, rats and swine can be constructed that overexpress mREC2 in only one particular tissue. In yet a further alternative embodiment the promoter can be an inducible promoter. An inducible promoter particularly suitable for the present invention is a tetracycline inducible promoter, which is described in U.S. Patent No. 5,464,758, which is incorporated by reference in its entirety.

Those skilled in the art will further appreciate that an mREC2 encoding gene can be constructed that contains some but not all introns of the complete mREC2 gDNA. Such a gene is a mixture of mREC2 gDNA and mREC2 cDNA fragments. As used herein the term "an mREC2 gene" is to be understood to denote, generically, mREC2 cDNA, mREC2 gDNA or a nucleic acid encoding a full length REC2 protein comprising mREC2 gDNA and mREC2 cDNA fragments.

The present invention further encompasses the use of mREC2 expression vectors to facilitate the construction of transgenic animals using cultured embryonic stem cells ("ES cells") according to the method of Capecchi, M.R., 1989, Science 244: 1288 and U.S. Patent 5,487,992, Col. 23-24, which are incorporated by reference in their entirety. A transgenic mouse having a inducible mREC2 gene introduced can be constructed. ES cells from such a transgenic mouse can be obtained and induced to have elevated levels of mREC2. Such cells will more readily undergo homologous recombination with a chimeric mutational vector ("CMutV"), an oligonucleotide having a similar structure and function to those of CRV, that can be used to introduce specific mutations into targeted wild-type genes. By use of CMutV, second and higher generation transgenic animals having further targeted genetic alterations can be constructed.

A further embodiment of the invention concerns the use of isolated and purified mREC2 protein in the construction of transgenic animals. Those skilled in the art of constructing transgenic animals understand that transgenic animals are constructed by

direct injection of a nucleic acid into the pronucleus of an ovum according to the method described Brinster, R.L. et al., 1989, PROC. NATL. ACAD. SCI 86:7087; see also U.S. Patent No. 4,873,191 to T.E. Wagner and P.C. Hoppe, which are hereby incorporated by reference in their entirety. Such direct injection results in the random integration of the injected nucleic acid. As noted above techniques for the introduction of transgenes by homologous recombination have been developed, however, such techniques require a specialized embryonic stem cell line, which is available only for mice, and, in addition require that the genetic alteration be designed so that homologous recombinants can be selected in culture, since the rate of homologous recombination is very low.

Because the use of the present invention in conjunction with CMutV permits a specific alteration to be introduced into a large fraction, e.g., 80%, of the copies of a target gene, those skilled in the art will appreciate that the invention provides a practical technique for the construction of transgenic animals wherein the function of both alleles of a specifically targeted gene has been deleted ("knocked-out") by homologous recombination using ova directly injected with a REC2 CMutV mixture.

Transgenic animals are constructed according to the invention by injecting a ova pronuclei with mREC2 protein and the CMutV. In a preferred embodiment a mixture of the CMutV and a mREC2 protein is injected into the ova pronucleus. In a preferred embodiment the nucleic acid to be injected is a CMutV that introduces a stop codon or a frameshift mutation into the gene to be knocked out. The concentration of protein to be used is about one molecule of mREC2 protein per between 5,000 base pairs and 50 base pairs of the CMutV, preferably one molecule of mREC2 protein per about 100-500 base pairs of the CMutV. Alternatively, the CMutV can be replaced by a conventional linearized DNA fragment containing homologous regions flanking a mutator region.

5.4 THE CONSTRUCTION OF *muREC2*-KNOCK-OUT MICE

The invention additionally provides transgenic mice that contain inactivated *muREC2*. Such heterozygous *muREC2*-knock-out transgenic mice can be constructed by injection of a murine embryonic blastocyst with an embryonic stem cell line (ES cells) that has the appropriate mutation in *muREC2* (*muREC2*^{ko}). The technique of Nichols, J., et al., 1990, DEVELOPMENT 110:1341-48 can be used. Further teaching regarding the

construction of transgenic mice using embryonic stem cell-injected blastocysts can be found in U.S. Patent No. 5,487,992 to Capecchi and Thomas, which is hereby incorporated by reference in its entirety. Homozygous *muREC2*-knock-out mice can be obtained by the intercross of heterozygous *muREC2*-knock-out mice and selection of offspring that are homozygous for the *muREC2*^{ko} allele.

Without limitation, a *muREC2*^{ko} gene can be made in two ways. A CMutV can be constructed according to U.S. patent No. 5,565,350, which is designed to introduce one or more stop codons at different positions within *muREC2* (an "*muREC2*^{ko} chimeric vector"). ES cells line can be treated with the *muREC2*^{ko} chimeric vector. Preferably several *muREC2*^{ko} chimeric vectors, designed to introduce redundant stop codons are used to reduce the reversion rate. After treatment, the ES cells can be cloned and the loss of a functional *muREC2* gene confirmed by sequence analysis or by PCR amplification using primers specific for the mutated codons.

Alternatively, a dicistronic targeting construct can be used to introduce a *muREC2*^{ko} mutation. Mountford, P., et al., 1994, Proc. Natl. Acad. Sci. 91:4303-07. More specifically, targeting vector is constructed having a cassette consisting of, in 5' to 3' order, a splice acceptor site, the 500 bp internal ribosome entry site (IRES) from encephalomyocarditis virus (EMCV), a fusion gene β geo, that has both β -galactosidase and G418 resistance activity, and an polyadenylation signal from SV40. In the targeting construct, the cassette is inserted, as an example without limitation, between two fragments from the introns 3' and 5' of the second exon of the *muREC2* gene, wherein the 5' most exon is the first exon, the exon immediately 3' to the 5'-most exon is the second exon etc. The length of the fragments can be preferably between about 500 bp and 5,000 bp.

The linearized targeting construct can be introduced into an ES cells by any technique suitable for the transfection of DNA into ES cells. The *muREC2* gene of the transfected ES cells undergoes homologous recombination whereby the cassette replaces the second exon such that the cassette is transcribed from the *muREC2* promoter and the β geo protein is translated by ribosomes bound to the IRES. ES cells having the cassette integrated into transcriptionally active genes can be selected by exposing the transfected cells to G418 and by histochemical staining to detect galactosidase positive cells.

Typically as many as 70% to 90% of β gal⁺/neo^r double transformants have undergone homologous recombination of the targeted gene.

Homozygous *muREC2*^{ko} mice have an increased susceptibility to mutation caused by chemical and physical agents. Such animals can be used to determine if products are mutagenic and more specifically if such products are carcinogens. Both homozygous and heterozygous *muREC2*^{ko} mice will also be more susceptible to the development of benign and malignant tumors. These animals can be used to originate tumors of different tissue types for use in biomedical studies.

5.5 THE CLASSIFICATION OF SAMPLES OF HUMAN TISSUE BY EXAMINATION OF THE *hsREC2* GENES OF THE SAMPLE

Those skilled in the art appreciate that there is a close connection between the a cell's capacity to remove chemically induced mutations and replication errors from its DNA and the cell's potential to develop the genetic changes that result in the development and progression of malignancies. Altonen, L.A., 1993, Science 260:812-816; Chung, D.C., & Rustgi, A.K., 1995, Gastroenterology 109:1685-99. A cell's capacity to remove mutations and replication errors can be classified by determining, firstly, whether the cell contains the normal, i.e., diploid number of copies of a gene that is essential for DNA mismatch repair and, secondly, by determining whether the copies that are present have been altered, i.e., contain mutations. Cells having a diminished capacity to remove DNA mismatches because of defects in their REC2 are malignant or are more likely to become malignant due to the further accumulation of mutations.

In one embodiment, the invention consists of classifying a human tissue according to the number of copies of the *hsREC2* gene per diploid genome. The reduction of the number to less than two indicates that some cells of the tissue can have a reduced capacity to repair DNA mismatches, because a mutation in the remaining copy would cause the absence of ATP-dependent homologous pairing activity. The number of copies of a gene can be readily determined by quantitative genomic blotting using probes constructed from labelled nucleic acids containing sequences that are fragment of SEQ ID NO:2 or a complement thereof. An alternative method of determining the number of *hsREC2* genes per diploid genome in a sample of tissue relies on the fact that the *hsREC2* gene is located in bands 14q23-24 and, particularly, that it is tightly linked to the

proximal side of the marker D14S258 and also tightly linked to the marker D14S251. The loss of a copy of a *hsREC2* gene in an individual who is heterozygous at a locus linked to the D14S258 marker can be inferred from the loss of the heterozygosity.

An alternative embodiment of the invention consists of classifying a sample of human tissue according to whether or not it contains an unmutated copy of a *hsREC2* gene. The *hsREC2* gene of the sample and the *hsREC2* of a standard tissue can be compared by any technique known to those skilled in the art or to be developed. A sensitive technique suitable for the practice of this embodiment of the invention is single strand conformational polymorphism (SSCP). Orita, M., et al., 1989, *Genomics* 5:874-879; Hayashi, K., 1991, *PCR Methods and Applic.* 1:34-38. The technique consists of amplifying a fragment of the gene of interest by PCR; denaturing the fragment and electrophoresing the two denatured single strands under non-denaturing conditions. The single strands assume a complex sequence-dependent intrastrand secondary structure that affects the strands electrophoretic mobility. Therefore comparison of an amplified fragment of a *hsREC2* gene from a sample of tissue with the amplified fragment from a *hsREC2* gene of a standard tissue is a sensitive technique for detecting mutations in the *hsREC2* of the sample.

The absence of a copy of an unmutated *hsREC2* gene in a sample of tissue indicates that the cells of the tissue have undergone or likely will undergo transformation into a malignant phenotype.

In a further alternative embodiment of the tissue sample can be classified by Southern blotting of the DNA of the sample. The presence of tissue specific bands in the blot is evidence that at least one copy of the *REC2* gene of the sample has undergone a mutational event. In yet a further embodiment of the invention, the tissue sample can be classified by amplifying a fragment of the *REC2* gene, by PCR, and analyzing the fragment by sequencing or by electrophoresis to determine if the sequence and length of the amplified fragment is that which can be expected from a normal *REC2* gene.

Without limitation, particular types of tissue samples that can be classified according to the invention include tumors which are associated with cytogenetic abnormalities at bands 14q23-24. Such tumor types include renal cell carcinomas and ovarian cancers Mittelman, F., 1994, *Catalog of Chromosome Aberrations in Cancer*,

(Johansson, B. and Mertens, F. eds.) Wiley-Liss, New York, pp 2303-2484. Also suitable for classification according to the method of the invention are tumor types that show a loss of heterozygosity of markers linked to the region 14q23-24. Such tumor types include meningiomas, neuroblastomas, astrocytomas and colon adenomas. Cox, D.W., 1994, Cytogenetic Cell Genet. 66:2-9. Of particular interest is the high rate of breast adenocarcinomas that have been found to have either mutated *hsREC2* genes or to have lost heterozygosity of the microsatellite DNA at the closely linked locus D14S258.

In addition to the above described methods the embodiments of the invention include a kit comprising a pair of oligonucleotides suitable for use as primers to amplify a fragment of a *hsREC2* gene, which pair consists of a 5'-primer having a sequence of a fragment of SEQ ID NO:2 and a 3'-primer having a sequence of a fragment of its complement wherein the 3'-primer is complementary to a portion of the sequence of SEQ ID NO:2 that lies 3' of the location of the 5'-primer sequence. The length of the 3' and 5'-primers is at least 12 nucleotides and preferably between about 16- and 25-nucleotides and more preferably between 18 and 24 nucleotides. The invention further consists of oligonucleotides having a sequence of a fragment of SEQ ID NO:2 or its complement and a label, which are suitable for hybridization with genomic blots of the *hsREC2* gene. Labels include radiolabels such as ³²P, fluorescent labels or any label known or to be developed that allows for the specific detection of a nucleic acid sequence.

The plasmid pcHsREC2, in which the *hsREC2* cDNA is operably linked to a CMV immediate early promoter has been deposited on August 20, 1996, in the ATCC, Rockville, MD, and accorded accession No. 97685. The plasmid was deposited under the name "pcHuREC2," but is referred to herein as pcHsREC2 for consistency. The plasmid pcHsREC2 is derived from commercially available plasmid pcDNA3 (Invitrogen, Inc.) and contains a 1.2 Kb insert that encodes *hsREC2*, which can be removed from pcHsREC2 by cutting with the restriction enzymes XbaI and KpnI.

EMBL-3-type λ phage clones, designated λ 5A and λ 1C, which contain a 12 Kb and 16Kb fragment of the 5' and 3' region of the *hsREC2* gene, respectively, were deposited on August 20, 1996, as accession No. 97683 and No. 97682, respectively.

AFIXII type λ phage clones, designated λ 5D2a and λ 7B1a, which contain a 14 Kb

and 14.9Kb fragment of the 5' and 3' region of the *muREC2* gene of strain 129SVJ, respectively, were deposited on August 22, 1996 and August 20, 1996, as accession No. 97686 and No. 97684, respectively. The inserts of λ 5D2a and λ 7B1a are released by cutting with a NotI restriction enzyme.

5.6 THE REC2 PROMOTER

The promoters of *hsREC2* and *muREC2* were cloned. The *hs REC2* promoter was cloned by a two step PCR-based promoter walking technique. Briefly, blunt ended genomic fragments are made by digestion with *DraI* and *SspI*, in the first and second step respectively. The restriction fragments are ligated to adapters. A primary PCR amplification is performed using a gene specific primer from the 5' extreme of the gene and an adapter specific primer. A secondary PCR is performed using nested, gene and adapter specific primers. The first step, primary and secondary gene specific primers were 5-CAG ACG GTC ACA CAG CTC TTG TGA TAA-3' (SEQ ID NO:8) and 5'-ACC CAC TCG TTT TAG TTT CTT GCT AC-3 (SEQ ID NO:9), respectively. The second step promoter walking primary and secondary primers were 5'-TAG AGA GAG AGA GAG AGC GAG ACA G-3' (SEQ ID NO:10) and 5'-GTC GAC CAC GCG TGC CCT ATA G-3' (SEQ ID NO:11), respectively. The first step and second step fragments were 0.8 and 0.9 Kb in length respectively.

The *mu REC2* promoter was sequenced by digestion of the clone λ 5D2a with *XbaI*. The promoter was found on the largest fragment, of about 7 Kb. The sequences of the *hsREC2* and *muREC2* are given in Figures 7A-7C and 7D-7F respectively.

The level of *REC2* transcripts in cultured human foreskin fibroblasts had been shown to be increased when the cells were exposed to ^{137}Cs irradiation. Several yeast genes have been identified that are radiation inducible and the radiation sensitive cis-acting control sequences from the promoters of such genes have been identified. See references cited in footnotes to Tables I-III. The sequence of the *hsREC2* and *muREC2* promoters were therefore inspected for the presence of such sequences. Figure 7 demonstrates that numerous such sequences were present. Tables I-III show the sequence of the yeast UV responsive elements, their positions in the yeast gene in which they are found and the reference to the scientific publication where they are

described.

The radiation induceability of the hsREC2 gene was directly assayed using UV radiation and the luciferase reporter gene in transiently transfected HeLa cells. The hsREC2 promoter was operably linked to a luciferase reporter gene and to the SV40 enhancer, placed downstream of the poly A addition signal. Any strong enhancer can be used, e.g., the enhancer from Cytomegalovirus, Hepatitis B Virus, α -fetoprotein, Rous Sarcoma Virus or Simian Virus 40. In this construct hsREC2 promoter was, in the absence of radiation approximately as strong a promoter as the SV40 immediate early promoter. When the cells were UV irradiated ($35 \text{ J/m}^2 \text{ UV}$) the hsREC2 promoter showed an approximate two to three fold increase in activity. See Section 6.8, below.

A radiation induceable promoter can be used to increase the susceptibility of cells to radiation as, for example, in conjunction with radiation therapy of a cancer. A construct containing a hsREC2 promoter operably linked to a "suicide gene", e.g., herpes thymidine kinase, can be introduced into mitotically active cells using a retrovirus based vector. A tumor can be irradiated and, simultaneously, gancyclovir, a DNA antimetabolite prodrug that is converted by herpes thymidine kinase, can be administered.

Those skilled in the art appreciate that the activity of the REC2 promoter can be further localized by testing the activity of the fragment after deletions having been made. A functional, radiation induceable promoter that is smaller than the fragment of Figure 7 can be found. Accordingly as used herein a human REC2 promoter and a murine REC2 promoter is defined as a DNA having the sequence found in Figures 7A-7C or 7D-7F, respectively, or a fragment thereof, wherein said fragment is a promoter in HeLa cells. The terms hsREC2 promoter and muREC2 promoter refer to DNA molecules having the sequences found in Figures 7A-7C and 7D-7F respectively. A REC2 promoter from any species can be defined analogously. Accordingly, in one embodiment, the invention concerns a composition containing a only a defined number of types of DNA molecules, one of which molecules comprises a REC2 promoter. As used herein such composition is said to comprise an isolated and purified REC2 promoter. In an alternative embodiment, the invention concerns a plasmid having a bacterial origin of replication (henceforth a "cloning plasmid"), which plasmid comprises a mammalian REC2 promoter and

specifically a human or a murine REC2 promoter. Those skilled in the art will further appreciate that the cis-acting radiation sensitive control elements present in the sequences of Figure 7 can be identified by systematic testing of fragments having the appropriate deletions. Accordingly, there can be REC2 promoters, as defined above, that are less radiation inducible than the hsREC2 promoter. As used herein a mammalian REC2 promoter is said to be radiation inducible if the promoter shows at least a two fold increase in activity and a REC2 promoter is termed "three fold inducible" if it shows a three fold increase when tested under the conditions wherein hsREC2 gives at least a four fold increase.

In further embodiments the REC2 promoter is operably linked to an enhancer. The present invention is illustrated by use of the SV40 enhancer. Those skilled in the art appreciate that any enhancer that is as strong as the SV40 enhancer can be used. Alternative enhancers include Cytomegalovirus, Hepatitis B Virus, α -fetoprotein, Rous Sarcoma Virus or Simian Virus 40 enhancers.

Table I UASs of <i>Saccharomyces cerevisiae</i> DNA repair genes				
Gene	Location	Sequences	SEQ ID NO	References
PHR1	-103	CGAGGAAGCAGT	15	13, 14
	-110	CGAGGAAGAAAA	16	
RAD2	-166	GGAGGCATTAAA	17	5
RAD23	-295	GGTGGCGAAATT	18	15, 16
RAD51	-215	CGTTACCCCTAT	19	
RAD54	-256	CGTTACCCAAT	20	
Consensus		GGAGGARRNANA C T C		

Table II. UASs of *Saccharomyces cerevisiae* DNA repair genes

Gene	Location	Sequences	SEQ ID NO.	References
Rhp51+	-290	CGTT_CCCTAT	21	11
	-260	CCTA_CCCTAA	22	
RAD51	-215	CGTTACCCTAT	23	12
RAD54	-256	CGTTACCCAAT	24	17
RNR3	-429	CGGTTGCCATG	25	18
Consensus		CGTTACCCTAT	26	

Table III. URSs of *Saccharomyces cerevisiae* DNA repair genes

Gene	Position	Sequences	SEQ ID NO	References
MAG	-215	GTAGGTCGAA	27	1
PHR1	-103	CGAGGAAGCA	28	2
	-109	CGAGGAAGAA	29	2
RAD2	-169	CGTGGAGGCA	30	1, 2, 3, 4, 5
RAD51	-157	CGTGGTGGGA	31	6, 12
DDR48	-271	CGAGGATGAC	32	1, 7
	-322	CGTGGTTGAT	33	1, 7
RNR2	-374	CGAGGTCGCA	34	8, 9
RNR3	-467	CTAGGTAGCA	35	1, 10
rhp51+	-233	GTAGGTGTTA	36	11
	-213	CTAGGTAACA	37	11
RAD16	-309	CATGGTTGCC	38	1
Consensus		CGTGGTNGAA	39	1
		A A CC		

References to Tables I-III:

1. Xiao W. et. al., 1993, *Mol. Cell. Biol.*, **13**, 7213-7221
2. Sebastian. J. et. al., 1990, *Mol. Cell. Biol.*, **10**, 4630-4637
3. Madura, K. et. al., 1986, *J. Bacteriol.*, **166**, 914-923
4. Reynolds, P. et. al., 1985, *EMBO J.*, **4**, 3549-3552
5. Siede, W. et. al., 1989, *Mol. Microbiol.*, **3**, 1697-1707
6. Basile, G. et. al., 1992, *Mol. Cell. Biol.*, **12**, 3235-3246
7. Treger, J. M. et. al., 1990, *Mol. Cell. Biol.*, **10**, 3174-3184
8. Elledge, S. J. et. al., 1989, *Mol. Cell. Biol.*, **9**, 5373-5386
9. Hurd, H. K. et. al., 1989, *Mol. Cell. Biol.*, **9**, 5359-5372
10. Yagle, K. et. al., 1990, *Mol. Cell. Biol.*, **10**, 5553-5557
11. Jang, Y. K. et. al., May 23, 1996, *Molecular & General Genetics*, **251** (2), 167-175,
12. Aboussekhra A. et. al., 1992, *Mol. Cell. Biol.*, **12**, 3224-3234
13. Sancar, G. B., 1985, *Nucleic Acids Research*, **13**, 8231-8246
14. Sancar, G. B. et. al., 1995, *Nucleic Acids Research*, **23**, 4320-4328
15. Jones, J. S. et. al., 1991, *Nucleic Acids Research*, **19**, 893-898
16. Watkins, J. F. et. al., 1993, *Mol. Cell. Biol.*, **13**, 7757-7765
17. Cole, G. M. et. al., 1989, *Mol. Cell. Biol.*, **9**, 3314-3322
18. Elledge S. J. et. al., 1989a, *Mol. Cell. Biol.*, **7**, 4932-4940

5.7

REC2-TRANSECTANTS ARE SENSITIZED TO IRRADIATION

One embodiment of the present invention is a plasmid or other isolated purified DNA molecule in which a mREC2 cDNA is operably linked to a strong promoter, which is preferably a constitutive promoter, e.g., a CMV immediate early promoter. In a further embodiment the invention consists of a mammalian cell that is transfected with such plasmid or isolated purified DNA and which over expresses Rec2. The overexpression of Rec2 causes a mammalian cells to be hypersensitive to DNA damaging agents such as alkylating agents, e.g., cyclophosphamide, γ-ray or UV-irradiation.

Accordingly, the present invention can be used to sensitize a set of cells that can be selectively transfected with a Rec2 expressing plasmid. Such sensitization can be used in conjunction with conventional oncologic chemotherapy or irradiation therapy to treat malignant disease.

6. EXAMPLES

6.1

**The production of recombinant hsREC2 protein
by baculovirus infection of *Autographica
californica***

To facilitate the construction of an *hsREC2* expression vector, restriction sites for XhoI and KpnI were appended by PCR amplification to a the *hsREC2* cDNA. The *hsREC2* cDNA starting at nt 71 was amplified using the forward primer 5'-GAG CTCGAG GGTACC C ATG GGT AGC AAG AAA C-3' (SEQ ID NO:14), which placed the XhoI and KpnI sites (underlined) 5' of the start codon. The recombinant molecule containing the entire coding sequence of *hsREC2* cDNA, can be removed using either XhoI or KpnI and the unique XbaI site located between nt 1270 and 1280 of SEQ ID NO:2.

A vector, pBacGSTSV, for the expression of HsREC2 in baculovirus infected *Spodoptera frugiperda* (Sf-9) insect cells (ATCC cell line No. CRL1711, Rockville MD), was obtained from Dr. Zailin Yu (Baculovirus Expression Laboratory, Thomas Jefferson University). The vector pVLGS was constructed by the insertion of a fragment encoding a *Schistosoma japonicum* glutathione S-transferase polypeptide and a thrombin cleavage site from pGEX-2T (described in Smith & Johnson, GENE 67:31 (1988)), which is hereby incorporated by reference, into the vector into the vector pVL1393. A polyA termination

signal sequence was inserted into pVLGS to yield pBacGSTSV. A plasmid containing the 1.2 Kb *hsREC2* fragment was cut with KpnI, the 3' unpaired ends removed with T4 polymerase and the product cut with XbaI. The resultant fragment was inserted into a SmaI, XbaI cut pBacGSTSV vector to yield pGST/*hsREC2*.

Recombinant virus containing the insert from pGST/*hsREC2* were isolated in the usual way and Sf-9 cells were infected. Sf-9 cells are grown in SF900II SFM (Gibco/BRL Cat # 10902) or TNM-FH (Gibco/BRL Cat # 11605-011) plus 10% FBS. After between 3-5 days of culture the infected cells are collected, washed in Ca^{++} and Mg^{++} free PBS and sonicated in 5ml of PBS plus proteinase inhibitors (ICN Cat # 158837), 1% NP-40, 250 mM NaCl per 5×10^7 cells. The lysate is cleared by centrifugation at 30,000 xg for 20 minutes. The supernatant is then applied to 0.5 ml of glutathione-agarose resin (Sigma Chem. Co. Cat # G4510) per 5×10^7 cells. The resin is washed in a buffer of 50 mM Tris-HCl, pH 8.0, 150 mM NaCl and 2.5 mM CaCl_2 , and the *hsREC2* released by treatment with thrombin (Sigma Chem. Co. Cat # T7513) for 2 hours at 23°C in the same buffer. For certain experiments the thrombin is removed by the technique of Thompson and Davie, 1971, *Biochim Biophys Acta* 250:210, using an aminocaproyl-p-chlorobenzylamide affinity column (Sigma Chem. Co. Cat # A9527).

6.2 Detection of the Enzymatic Properties of *hsREC2* protein

Baculovirus produced hexahistidyl*hsREC2* was tested in a DNA reannealing assay as described in Kmiec, E.B., & Holloman, W.K., 1982, *Cell* 29:367-74. The results, Figure 3, showed that *hsREC2* catalyzes the reannealing of denatured DNA. An optimal reaction occurred at about 1 *hsREC2* per 50-100 nucleotides.

Further studies to characterize *hsREC2* showed that it catalyzes the reaction $\text{ATP} \rightarrow \text{ADP} + \text{PO}_4$. Similar to *recA*, at ATP concentrations of $< 100 \mu\text{M}$, there is cooperativity between *hsREC2* molecules; the Hill coefficient (1.8) suggests that the functional unit for ATP hydrolysis is at least a dimer. Gel retardation experiments were performed to determine the ATP dependence of *hsREC2* binding to ssDNA. The results of these experiments showed that *hsREC2* binds ssDNA only in the presence of ATP or its non-hydrolyzable thio analog $\gamma\text{-SATP}$. Figure 4. Again the *hsREC2* results parallel those of *recA*.

Further examples of specific assays using isolated and purified hsRec2 are as follows:

6.2.1 Binding to Single Stranded DNA

A 73 nucleotide single stranded DNA (SS) was ^{32}P end labelled using polynucleotide kinase. DNA binding was carried out using 0.25 ng of labeled SS in 25 mM Tris-HCl, pH 7.4, 10 mM MgCl_2 , 4 mM ATP, and 1 mM DTT and protein. hsRec2-thioredoxin was partially purified on a Thiobond™ column (Invitrogen) and desalted/concentrated using a Microcon 30 spin column (Amicon). Approximately 0.3 μg protein was added. The reaction mixture was incubated 30 min. at 37°C, following which sucrose was added to facilitate loading onto a polyacrylamide gel. The mixture was loaded onto a 12% nondenaturing gel in 90 mM Tris, 90 mM borate, pH 8.3, 2 mM EDTA for 3 hours at 150 V. The gel was then dried and exposed overnight. Approximately 3% of the label was retarded in the presence of ATP or $\gamma\text{S-ADP}$, while reduced amounts of label were bound in the absence of either of ATP or $\gamma\text{S-ADP}$.

6.2.2 Catalysis of Reannealing of DNA

Reannealing of a 123 nucleotide fragment was determined as follows. The single stranded 123 nucleotide (SS) was ^{32}P end labelled using polynucleotide kinase. Varying amounts of affinity purified GST-hsRec2 fusion protein was added to 0.5 ng of SS in 25 μl of 20mM TrisHCl pH 7.5, 10 mM MgCl_2 , 0.5 mM DTT with 5 mM ATP optionally present. Samples were incubated 30 min. at 37°C, followed by phenol/chloroform extraction to stop the reaction, followed by a second 30 min. incubation at 37°C. The reaction mixture was then electrophoresed as in section 6.2.1, above, and autoradiographed. The results, shown in Figure 6, demonstrate that GST-hsREC2 catalyzes the reannealing of the SS in both the presence and absence of ATP.

6.3 Overexpression of *hsREC2* Suppresses UVC-Induced Mutation

To determine whether the presence of hsRec2 protects cultured cells from UVC induced mutation a CHO cell line was transfected with a mixture of linearized pcHsREC2 and pCMVneo and a clone resistant to G418 was selected ("15C8 hsREC2"). Elevated levels of hsREC2 expression were confirmed by immunoblotting using rabbit antisera raised to baculovirus produced hsRec2 fusion proteins.

Mutability was determined as follows. 1.6×10^6 15C8 hsREC2 cells were plated in a 100 mm petri dish and exposed to 0 or between 2.0 and 5.0 J/m² UV radiation. After 7 days of culture, the remaining cells were exposed to 40 μ M 6-TG. Surviving cells had undergone an inactivation of the HPRT gene. After a further 7-10 days of culture the number of colonies was counted. The mutation frequency was adjusted for the cloning efficiency of the population which was determined by plating a limiting number of cells without 6-TG.

The results showed that the untransfected, pCMVneo and 15C8 hsREC2 cells had mutation rates of 1.7, 6.2 and 0.4 per million, respectively, without UVC irradiation. After UVC radiation the mutation rates observed were, in three experiments, between 94 and 16, 61 and 74, and 3 and 37, per million, for untransfected, pCMV transfected and 15C8 hsREC2 cells, respectively. Thus, the expression of *hsREC2* caused a marked decrease in the susceptibility of CHO cells to UVC induced mutation as well as a drop in the spontaneous mutation frequency.

6.4 Enhanced Repair of β -globin in Cultured, EB-transformed Human Lymphoblasts

SC1, a chimeric vector designed to repair the mutation found in Sickle Cell Disease β -globin, contained two blocks of ten 2'-O-methyl RNA residues each, flanking an intervening block of five DNA residues, see Figure 5B. When the molecule was folded into the duplex conformation, one strand contained only DNA residues while the other strand contained the RNA/DNA blocks. In this case, the internal sequence is complementary to the β^S globin sequence over a stretch of 25 residues that span the site of the β^S mutation, with the exception of a single base (T) which is in bold and designated with an asterisk. The five DNA residues flanked by RNA residues were centered about the mutant T residue in the β^S coding sequence. Genomic sequences of the β^A , β^S , and closely-related δ -globin genes are also displayed in Figure 3 with the specific site of β^S mutation printed in bold.

Lymphoblastoid cells were prepared as follows. Heparin-treated blood was obtained from discarded clinical material of a patient with sickle cell disease. Mononuclear cells were prepared from blood (≈ 8 ml) by density gradient centrifugation in Ficoll and

infected with Epstein-Barr virus which had been propagated in the marmoset cell line B95-8 (Coriell Institute for Medical Research #GM07404D). Infections were performed with addition of 0.1 mg leucoagglutinin PHA-L in 10 ml RPMI medium supplemented with 20% fetal bovine serum in a T25 flask. Cultures were fed twice a week starting on day 5 and were considered established once 60-70% of the cells remained viable at day 21. The β^A and β^S lymphoblastoid cells were maintained in RPMI medium containing 10% fetal bovine serum.

The EBV-transformed lymphoblastoid cells were transiently transfected with either the vector pcDNA3 or the vector having inserted *hsREC2* cDNA (pcHsREC2). Transfection was done using mixtures of 15 μ l DOTAP and 2.5 μ g DNA, as detailed below. After transfection the cells were incubated for 24 hours and then treated with varying amounts of SC1.

SC1 was introduced into the above-described lymphoblastoid cells homozygous for the β^S allele as follows. Cells (1×10^5 per ml) were seeded in 1ml of medium in each well of a 24-well tissue culture plate the day prior to the experiment. Transfections were performed by mixing chimeric oligonucleotides in amounts ranging from 0 to 250 ng, with 3 μ l of DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate, Boehringer-Mannheim) in 20 ml of 20 mM HEPES, pH 7.3, incubated at room temperature for 15 min, and added to the cultured cells. After 6 h the cells were harvested by centrifugation, washed and prepared for PCR amplification following the procedure of E.S. Kawasaki, PCR Protocols, Eds. M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White, pp146-152, Academic Press, (1990).

Correction of the single base mutation was assessed by taking advantage of well known restriction fragment length polymorphisms resulting from the β^S mutation, R.F. Greeves et al., 1981, Proc. Natl. Acad. Sci. 78:5081; J.C. Chang and Y.W. Kan, 1982, N. Eng. J. Med. 307:30; S.H. Orkin et al., *ibid.*, p. 32; J.T. Wilson et al., 1982, Proc. Natl. Acad. Sci. 79:3628. The A to T transversion in the β^S allele results in the loss of a Bsu36I restriction site (CCTGAGG). Thus, the β^S allele can be detected by Southern hybridization analysis of genomic DNA cut with Bsu36I. A 1.2 Kb Bsu36I DNA fragment of the β -globin gene present normally is absent in the β^S allele and is replaced by a diagnostic 1.4 Kb fragment. When genomic DNA recovered from homozygous β^S

lymphoblastoid cells was analyzed by this procedure, the expected 1.4 Kb fragment was observed. However, two fragments were observed in DNA from cells transfected with the SC1 CRV. The presence of the 1.2 Kb fragment in addition to the 1.4 Kb fragment indicates partial correction of the β^S allele had taken place in a dose-dependent fashion.

The results of the experiment are shown in Figure 5A. At 100 ng and 250 ng of SC1 between 65% and 85% of the β^S alleles were mutated to β^A alleles in the cells pre-transfected with pcHsREC2, compared to between 10% and 25% in the non pre-transfected cells and negligible levels in the control transfected cells. At levels of SC1 between 25 ng and 50 ng of SC1, no mutations were detected in any of the control cell populations while between 30% and 40% of the β^S alleles were mutated to β^A alleles in the cells pre-transfected with pcHsREC2.

These results show that the over expression of *hsREC2* causes marked increase in the susceptibility of a cell to mutation by a chimeric mutation vector such as SC1.

6.5 Identification and Isolation of mREC2 gDNA Clones

Genomic blots of human and murine, strain 129 SVJ, DNA were made using XbaI and BamHI digests. Following transfer to Zeta-Probe™ membranes (Bio-Rad) the membranes were prehybridized for 30' at 55°C in 0.25M NaHPO₄, pH7.2, 7% SDS, 1 mM EDTA and hybridized overnight with a random primed full length HsREC2 probe. Wash was 2X for 20' at 42°C in 0.04M NaHPO₄, pH7.2, 5% SDS, 1 mM EDTA and 1X each at 42°C and 50°C for 20' in 0.04M NaHPO₄, pH7.2, 1% SDS, 1 mM EDTA. The results were bands of the following sizes: Human-XbaI 6.0, 4.1, 2.6, 2.0 and 1.5 Kb; Human-BamHI 9.5, 8.5, 6.5, 4.6, 1.5 Kb; Murine-XbaI 9.0, 6.0, 4.1, 3.5, 1.9, 0.8 Kb; and Murine-BamHI 8.0, 2.7 and 1.8.

To identify and propagate clones containing mREC2 from cDNA or DNA libraries standard techniques for cloning were employed using λ -phage libraries. A human genome library in EMBL-3 and a murine genomic library in λ FIXII were screened. Phage plaques were transferred to hybridization filters by standard techniques and the filters were probed with radiolabelled *hsREC2* cDNA. After hybridization the filters were washed. A wash consisting of twice at 42°C for 20' in 2x SSC, 0.1% SDS followed by thrice at 50°C for 20' in the same solution was used to isolate murine gDNA clones. To

isolate human gDNA clones a the wash procedure was: twice 20 min. at 42°C in 40 mM NaHPO₄, pH 7.2, 1 mM EDTA, and 5% SDS; followed by once for 20 min. at 50°C in the same solution except for 1% SDS.

The 5' and 3' fragments of *muREC2* and *hsREC2* gDNA were recovered in the following λ phage clones: λ 5D2a (14 Kb insert, 5' *muREC2*); λ 7B1a (14.9 Kb insert, 3' *muREC2*); λ 5A (12 Kb insert, 5' *hsREC2*); λ 1C (16 Kb insert, 3' *hsREC2*), each of which has been deposited in the ATCC, Bethesda, MD.

Fragments of genomic clones can be used as probes of genomic blots to identify rearrangements deletions or other abnormalities of *hsREC2* in tumor cells. Those skilled in the art further appreciate that by routine sequence analysis and comparison with the sequence of SEQ ID NO: 2, the boundaries of the exons and introns of *hsREC2* can be identified. Knowing the sequence of at the intron/exon boundaries allows for the construction of PCR suitable for the amplification and analysis of each exon as alternatives to the methods of section 6.6.

6.6 Elevated Incidence of Abnormalities in *hsREC2* in Adenocarcinomas of the Breast

Samples of 30 primary ductal carcinoma of the breast were analyzed by Southern blot, probed with the *hsREC2* cDNA and by a high resolution gel of the PCR product of the microsatellite marker D14S258, which is closely linked to the *hsREC2* gene. Ten of the thirty samples gave abnormal results in one of the two assays and 3 showed abnormalities by both assays. In contrast none of 16 samples of primary renal cell carcinoma showed clear abnormalities in a Southern blot.

6.6.1 Loss of Heterozygosity of Microsatellite DNA Linked to *hsREC2*

The location of *hsREC2* was found to be tightly linked to the proximal side of the microsatellite marker D14S258. Because there is extensive polymorphism in the lengths of microsatellite sequences most individuals are heterozygous at the D14S258 locus. Primers specific for unique sequences flanking the polymorphic locus can be used to generate PCR fragments whose length is allele specific. Primers specific for D14S258 were obtained from the Dr. Lincoln Stein, Whitehead Institute, MIT, Cambridge MA. The "5'" primer is 5'-TCACTGCATCTGGAAGCAC-3' (SEQ ID NO:12) and the "3'" primer is

5'-CTAACTAAATGGCGAGCATTGAG-3' (SEQ ID NO:13). PCR was performed with a genomic DNA concentration of 2.0 ng/ μ l, a primer concentration of 10.0 μ M, 10.0 μ M dNTP, 500 μ M Tris HCl, pH 9.2, 17.5 μ M MgCl₂, 160 μ M (NH₄)₂SO₄, and a polymerase concentration of 0.03 U/ μ l. Amplification was performed for 35 cycles of 50 seconds each, alternating between 57°C and 94°C, followed by an extension of 7 minutes at 72°C and preceded by an initial heat soak of 5 minutes at 94°C. The expected product is about 160-170 nucleotides in length.

A comparison of the products of PCR amplification of tumor and normal tissue control DNA using the flanking primers can reveal the loss of either or both D14S258 loci, which suggests that the linked *hsREC2* has also been lost.

The results of analysis 7 of 30 samples breast tumors showed a complete or partial loss of one allele at locus D14S258.

These results show that instability and loss of a genetic locus tightly linked to the location of *hsREC2* is found in a large fraction of human ductal adenocarcinoma of the breast.

6.6.2 Frequent Rearrangements of *hsREC2*

Genomic DNA from samples of 16 primary renal and 30 primary breast tumors tumor tissue were digested with either XbaI or BamHI restriction enzymes, electrophoresed in a 0.8% agarose gels and processed for hybridization with labeled random primed copies made from the *hsREC2* cDNA. After transfer, Zetaprobe™ blotting membranes were UV crosslinked, prehybridized at 65°C for 20 min in 0.25M NaHPO₄, pH 7.4, 7% SDS, 1mM EDTA and then hybridized overnight under the same conditions. The membranes were pre-washed once with 40mM NaHPO₄, pH 7.2, 5% SDS, 1mM EDTA at 42°C for 20 min, then washed repeatedly at 60°C in the same solution, except for 1% SDS, until background levels were achieved in the periphery of the membrane. The filters were then exposed to film.

Six of the 30 examples of carcinoma of the breast showed rearrangements or abnormalities while none of the 16 samples of renal cell carcinoma showed clear rearrangements.

6.7 Construction of a MuREC2^{ko} containing ES cell line

The muREC2 gDNA clone λ 5D2a contains the first two exons. The second exon is located on 3.6 Kb Eco R1 fragment, approximately 1.2 Kb from the fragment's 5' border. The second exon contains a unique *Stu*I site into which was inserted the IRES- β geo poly A cassette, Mountford, P., et al., 1994, Proc. Natl. Acad. Sci. **91**, 4303-4307. ES cells were cultured on primary mouse embryo fibroblasts according to standard protocols, Hogan, B., et al., 1996, MANIPULATING THE MOUSE EMBRYO, Cold Spring Harbor Press. Approximately 2×10^7 ES cells were transfected by electroporation with 25 μ g linearized DNA. Selection was begun at 36 hours and continued until day 8 with 250 μ g/ml G418. Thirty colonies were isolated and tested by *Xba*I digest and Southern blot; one colony was found to lack the wild type size *Xba*I fragment and to have a novel fragment of the predicted size. Transgenic mice are constructed from this ES cell line by conventional techniques. *Ibid.*

6.8 The HsREC2 Promoter Is Radiation Induceable

A 1.8 Kb fragment immediately 5' to the hsREC2 start codon was cloned. The fragment was tested as a promoter using the luciferase reported gene construct, pGL2, (Promega Cat. No. E1611), luciferase activity was measured using the luciferase reported test kit (Boehringer Mannheim Cat. No. 1669 893).

The activity of the promoter is assayed in HeLa cells as follows. The HeLa cells are trypsinized on day -1 and plated at 6.6×10^5 / 60 mm well in 3.0 ml of DMEM. On day two at -1h the medium is replaced with serum free medium and the cells are transfected with various quantities of the plasmid with DOSPER at a DNA:DOSPER ratio of 1:4. At 5 hour an additional 3.0 ml of medium supplemented with FBS is added; at 24 hours the cells are irradiated with UV light (Stratalinker). Cells are harvested at 48 hours and proteins extracted and assayed. Control experiments done with the same plasmid having the SV40 immediate early promoter in place of the hsREC2 promoter.

UV Irradiation (Joules/meter ²)	DNA Added (Micrograms)			
	3 μ g	2.4 μ g	1.2 μ g	0.6 μ g
0 J/m ²	655.6 ¹	494 ²	27.5	32.8
15 J/m ²	951.5	1287	28.9	28.7
25 J/m ²	1033.6	1398	35.8	44.2
35 J/m ²	1134.6	1786	84.89	68.4

1. The corresponding luciferase is 513.9 pSV40-luc-SV40 enhancer at 0 Joules/meter².
2. The corresponding luciferase is 384 pSV40-luc-SV40 enhancer at 0 Joules/meter².

When the 3' 0.8 Kb of the hsREC2 promoter was tested beginning with nt 869 of SEQ ID NO: 5, it was determined that this 0.8 Kb fragment contains a promoter having reduced activity but which is also shows an about 5 fold induceability with 35 J/m² UV radiation in HCT 116, which cell line contains a normal p53 gene. The preferred form of the REC2 inducible promoter in HCT 116 is the shortened form starting at nt 869.

6.9 The Expression of REC2 Causes Increased Radiation Sensitivity

UV irradiation induces apoptosis in stable transfectants expressing wild-type HsRec2 but not truncated or full length with an altered tyrosine 163 site. In order to measure the effects of REC2 expression on the rate of UV induced radiation CHO cells were irradiated. During the 24 hour long recovery period following irradiation, more CHO cells expressing wild-type HsRec2 were observed to die than the control cells that expressed an irrelevant or nonfunctional proteins. To determine whether cell death was a result of apoptosis, asynchronous cells were irradiated at a dose of 15 J/m², and fixed in ethanol at 24, 48 and 72 hours following irradiation. FACS analysis was conducted as follows: Cells were trypsinized, washed once with PBS and fixed in 70% ethanol at least 30 minutes at 4°C Cell pellets were treated with DNase-free Rnase for 30 minutes at 70°C at a final concentration of 0.16 mg/ml and stained in propidium iodide (0.05 mg/ml)

for 15 minutes, then stored overnight prior to analysis by FACS. The FACS analysis and determination of the percentage of cells in G1, S and G2 phases (Multicycle Flow program) was carried out in the Cell Cycle Center at the Kimmel Cancer Institute of Thomas Jefferson University. Cells from duplicate cultures were harvested at the same time points, and frozen at -80°C . for DNA isolation. DNA was isolated using a QIAGEN Blood Kit (QIAGEN Inc., Chatsworth, CA) and stored at 4°C . until run on gels. DNA was run on 1% agarose gels in TAE buffer and stained 30 minutes with a 1:10,000 dilution of SYBR Green I (FMC, Rockland, ME). Gels were then scanned using a FluorImager (Molecular Diagnostics, San Diego, CA).

Four cell types were used for analysis; CHO cells containing the empty vector (Neo^r), CHO cells expressing HsRec2 Δ 103-350 (3D2), HsRec2^{ala63} (PH4), and the wild-type HsRec2 (15C8). A sub-G1 population was detected at 24, 48, and 72 hours following irradiation for CHO cells expressing the wild-type HsRec2 only. To confirm that apoptosis was occurring, DNA was isolated from cells, and run on a 1% agarose gel, stained with SYBR Green I and scanned. For each time interval compared, 15C8 exhibited a more pronounced ladder than the other clones. Although there appears to be a small amount of apoptosis for the clone expressing HsRec2^{ala63} it is considerably lower than for the wild-type HsRec2 clone, and neither the Neo^r or the transfectants expressing the truncated protein are comparable. Therefore, the G1 delay and apoptosis require the wild-type HsRec2, and suggests that perhaps cooperation between a mutant p53 present in CHO cells and Rec2 may be responsible for genome surveillance in these cells.

The results of the FACS analysis of the HsRec2 expressing and the Neo^r expressing clones are given in Figures 8A-8H.

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Kmiec, Eric B.

Holloman, William K.

Rice, Michael C.

Smith, Sheryl T.

Shu, Zhigang

(ii) TITLE OF THE INVENTION: Mammalian and Human Rec2

(iii) NUMBER OF SEQUENCES: 39

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Kimeragen, Inc.

(B) STREET: 300 Pheasant Run

(C) CITY: Newtown

(D) STATE: PA

(E) COUNTRY: USA

(F) ZIP: 18940

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(viii) ATTORNEY/AGENT INFORMATION:

- (A) NAME: Hansburg, Daniel
- (B) REGISTRATION NUMBER: 36156
- (C) REFERENCE/DOCKET NUMBER: 7991-010-999

(ix) TELECOMMUNICATION INFORMATION:

- (A) TELEPHONE: 215-504-4444
- (B) TELEFAX: 215-504-4545
- (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 350 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Gly Ser Lys Lys Leu Lys Arg Val Gly Leu Ser Gln Glu Leu Cys
 1             5             10             15
Asp Arg Leu Ser Arg His Gln Ile Leu Thr Cys Gln Asp Phe Leu Cys
      20             25             30
Leu Ser Pro Leu Glu Leu Met Lys Val Thr Gly Leu Ser Tyr Arg Gly
      35             40             45
Val His Glu Leu Leu Cys Met Val Ser Arg Ala Cys Ala Pro Lys Met
      50             55             60
Gln Thr Ala Tyr Gly Ile Lys Ala Gln Arg Ser Ala Asp Phe Ser Pro
65             70             75             80
Ala Phe Leu Ser Thr Thr Leu Ser Ala Leu Asp Glu Ala Leu His Gly
      85             90             95
Gly Val Ala Cys Gly Ser Leu Thr Glu Ile Thr Gly Pro Pro Gly Cys
      100            105            110
Gly Lys Thr Gln Phe Cys Ile Met Met Ser Ile Leu Ala Thr Leu Pro
      115            120            125
Thr Asn Met Gly Gly Leu Glu Gly Ala Val Val Tyr Ile Asp Thr Glu
      130            135            140

```

Ser Ala Phe Ser Ala Glu Arg Leu Val Glu Ile Ala Glu Ser Arg Phe
 145 150 155 160
 Pro Arg Tyr Phe Asn Thr Glu Glu Lys Leu Leu Leu Thr Ser Ser Lys
 165 170 175
 Val His Leu Tyr Arg Glu Leu Thr Cys Asp Glu Val Leu Gln Arg Ile
 180 185 190
 Glu Ser Leu Glu Glu Glu Ile Ile Ser Lys Gly Ile Lys Leu Val Ile
 195 200 205
 Leu Asp Ser Val Ala Ser Val Val Arg Lys Glu Phe Asp Ala Gln Leu
 210 215 220
 Gln Gly Asn Leu Lys Glu Arg Asn Lys Phe Leu Ala Arg Glu Ala Ser
 225 230 235 240
 Ser Leu Lys Tyr Leu Ala Glu Glu Phe Ser Ile Pro Val Ile Leu Thr
 245 250 255
 Asn Gln Ile Thr Thr His Leu Ser Gly Ala Leu Ala Ser Gln Ala Asp
 260 265 270
 Leu Val Ser Pro Ala Asp Asp Leu Ser Leu Ser Glu Gly Thr Ser Gly
 275 280 285
 Ser Ser Cys Val Ile Ala Ala Leu Gly Asn Thr Trp Ser His Ser Val
 290 295 300
 Asn Thr Arg Leu Ile Leu Gln Tyr Leu Asp Ser Glu Arg Arg Gln Ile
 305 310 315 320
 Leu Ile Ala Lys Ser Pro Leu Ala Pro Phe Thr Ser Phe Val Tyr Thr
 325 330 335
 Ile Lys Glu Glu Gly Leu Val Leu Gln Ala Tyr Gly Asn Ser
 340 345 350

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1797 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CGGACGCGTG GGC GCGGGGA AACTGTGTAA AGGGTGGGGA AACTGAAAG TTGGATGCTG 60
 CAGACCCGGC ATGGGTAGCA AGAACTAAA ACGAGTGGGT TTATCACAAG AGCTGTGTGA 120

```

CCGTCTGAGT AGACATCAGA TCCTTACCTG TCAGGACTTT TTATGTCTTT CCCCACTGGA 180
GCTTATGAAG GTGACTGGTC TGAGTTATCG AGGTGTCCAT GAACTTCTAT GTATGGTCAG 240
CAGGGCCTGT GCCCCAAAGA TGCAAACGGC TTATGGGATA AAAGCACAAA GGTCTGCTGA 300
TTTCTCACCA GCATTCTTAT CTA CTACTACCTT TTCTGCTTTG GACGAAGCCC TGCATGGTGG 360
TGTGGCTTGT GGATCCCTCA CAGAGATTAC AGGTCCACCA GGTGTGGAA AAACCTCAGTT 420
TTGTATAATG ATGAGCATTT TGGCTACATT ACCCACCAAC ATGGGAGGAT TAGAAGGAGC 480
TGTGGGTGAC ATTGACACAG AGTCTGCATT TAGTGCTGAA AGACTGGTTG AAATAGCAGA 540
ATCCCGTTTT CCCAGATATT TTAACACTGA AGAAAAGTTA CTTTTGACAA GTAGTAAAGT 600
TCATCTTTAT CGGGAACCTCA CCTGTGATGA AGTCTACAA AGGATTGAAT CTTTGGAAGA 660
AGAAATTATC TCAAAAGGAA TTAAACTTGT GATTCTTGAC TCTGTTGCTT CTGTGGTCAG 720
AAAGGAGTTT GATGCACAAC TTCAAGGCAA TCTCAAAGAA AGAAACAAGT TCTTGCCAAG 780
AGAGGCATCC TCCTTGAAGT ATTTGGCTGA GGAGTTTTCA ATCCCAGTTA TCTTGACGAA 840
TCAGATTACA ACCCATCTGA GTGGAGCCCT GGCTTCTCAG GCAGACCTGG TGTCTCCAGC 900
TGATGATTG TCCCTGTCTG AAGGCACTTC TGGATCCAGC TGTGTGATAG CCGCACTAGG 960
AAATACCTGG AGTCACAGTG TGAATACCCG GCTGATCCTC CAGTACCTTG ATTCAGAGAG 1020
AAGACAGATT CTTATTGCCA AGTCCCCTCT GGCTCCCCTC ACCTCATTG TCTACCCAT 1080
CAAGGAGGAA GGCCTGGTTC TTCAAGCCTA TGGAAATTCC TAGAGACAGA TAAATGTGCA 1140
AACCTGTTCA TCTTGCCAAG AAAAATCCGC TTTTCTGCCA CAGAAACAAA ATATTGGGAA 1200
AGAGTCTTGT GGTGAAACAC CCATCGTTCT CTGCTAAAAC ATTTGGTTGC TACTGTGTAG 1260
ACTCAGCTTA AGTCATGGAA TTCTAGAGGA TGTATCTCAC AAGTAGGATC AAGAACAAGC 1320
CCAACAGTAA TCTGCATCAT AAGCTGATTT GATACCATGG CACTGACAAT GGGCACTGAT 1380
TTGATACCAT GGCCTGACA ATGGGCACAC AGGGAACAGG AAATGGGAAT GAGAGCAAGG 1440
GTTGGGTTGT GTTCGTGGAA CACATAGGTT TTTTTTTTAA ACTTTCTCTT TCTAAAATAT 1500
TTCATTTTGA TGGAGGTGAA ATTTATATAA GATGAAATTA ACCATTTTAA AGTAAACAAT 1560
TCCGTGGCAA CTAGATATCA TGATGTGCAA CCAGCATCTC TGTCTAGTTC CCAAATATTT 1620
CATCACCCCC AAAAGCAAGA CCCATAACCA TTATGCAAGT GTTCCTATTT CCCCCTCCTC 1680
CCAGCTCCTG GGAAACCACC AATCTACTTT TTTTCTATGG CTTTACCTAA TCTGGAAATT 1740
TCAAATAAAT GGGATCAAAT AGTTTCCCAA AAAAAAAAAA AAAAAAAAAA AAAAAAA 1797

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 350 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ser Ser Lys Lys Leu Arg Arg Val Gly Leu Ser Pro Glu Leu Cys

1	5	10	15
Asp Arg Leu Ser Arg Tyr Leu Ile Val Asn Cys Gln His Phe Leu Ser			
20	25	30	
Leu Ser Pro Leu Glu Leu Met Lys Val Thr Gly Leu Ser Tyr Arg Gly			
35	40	45	
Val His Glu Leu Leu His Thr Val Ser Lys Ala Cys Ala Pro Gln Met			
50	55	60	
Gln Thr Ala Tyr Glu Leu Lys Thr Arg Arg Ser Ala His Leu Ser Pro			
65	70	75	80
Ala Phe Leu Ser Thr Thr Leu Cys Ala Leu Asp Glu Ala Leu His Gly			
85	90	95	
Gly Val Pro Cys Gly Ser Leu Thr Glu Ile Thr Gly Pro Pro Gly Cys			
100	105	110	
Gly Lys Thr Gln Phe Cys Ile Met Met Ser Val Leu Ala Thr Leu Pro			
115	120	125	
Thr Ser Leu Gly Gly Leu Glu Gly Ala Val Val Tyr Ile Asp Thr Glu			
130	135	140	
Ser Ala Phe Thr Ala Glu Arg Leu Val Glu Ile Ala Glu Ser Arg Phe			
145	150	155	160
Pro Gln Tyr Phe Asn Thr Glu Glu Lys Leu Leu Leu Thr Ser Ser Arg			
165	170	175	
Val His Leu Cys Arg Glu Leu Thr Cys Glu Gly Leu Leu Gln Arg Leu			
180	185	190	
Glu Ser Leu Glu Glu Glu Ile Ile Ser Lys Gly Val Lys Leu Val Ile			
195	200	205	
Val Asp Ser Ile Ala Ser Val Val Arg Lys Glu Phe Asp Pro Lys Leu			
210	215	220	
Gln Gly Asn Ile Lys Glu Arg Asn Lys Phe Leu Gly Lys Gly Ala Ser			
225	230	235	240
Leu Leu Lys Tyr Leu Ala Gly Glu Phe Ser Ile Pro Val Ile Leu Thr			
245	250	255	
Asn Gln Ile Thr Thr His Leu Ser Gly Ala Leu Pro Ser Gln Ala Asp			
260	265	270	
Leu Val Ser Pro Ala Asp Asp Leu Ser Leu Ser Glu Gly Thr Ser Gly			
275	280	285	
Ser Ser Cys Leu Val Ala Ala Leu Gly Asn Thr Trp Gly His Cys Val			
290	295	300	
Asn Thr Arg Leu Ile Leu Gln Tyr Leu Asp Ser Glu Arg Arg Gln Ile			
305	310	315	320
Leu Ile Ala Lys Ser Pro Leu Ala Ala Phe Thr Ser Phe Val Tyr Thr			
325	330	335	

Ile Lys Gly Glu Gly Leu Val Leu Gln Gly His Glu Arg Pro
 340 345 350

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1525 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

GGGAGCCCTG GAAACATGAG CAGCAAGAAA CTAAGACGAG TGGGTTTATC TCCAGAGCTG      60
TGTGACCGTT TAAGCAGATA CCTGATTGTT AACTGTCAGC ACTTTTAAAG TCTCTCCCCA      120
CTAGAACTTA TGAAAGTGAC TGGCCTGAGT TACAGAGGTG TCCACGAGCT TCTTCATACA      180
GTAAGCAAGG CCTGTGCCCC GCAGATGCAA ACGGCTTATG AGTTAAAGAC ACGAAGGTCT      240
GCACATCTCT CACCGGCATT CCTGTCTACT ACCCTGTGCG CCTTGGATGA AGCATTGCAC      300
GGTGGTGTGC CTTGTGGATC TCTCACAGAG ATTACAGGTC CACCAGGTTG CGGAAAAACT      360
CAGTTTTGCA TAATGATGAG TGTCTTAGCT ACATTACCTA CCAGCCTGGG AGGATTAGAA      420
GGGGCTGTGG TCTACATCGA CACAGAGTCT GCATTTACTG CTGAGAGACT GGTGAGATT      480
GCGGAATCTC GTTTTCCACA ATATTTTAAC ACTGAGGAAA AATTGCTTCT GACCAGCAGT      540
AGAGTTCATC TTTGCCGAGA GCTCACCTGT GAGGGGCTTC TACAAAGGCT TGAGTCTTTG      600
GAGGAAGAGA TCATTTTCGAA AGGAGTTAAG CTTGTGATTG TTGACTCCAT TGCTTCTGTG      660
GTCAGAAAGG AGTTTGACCC GAAGCTTCAA GGCAACATCA AAGAAAGGAA CAAGTTCTTG      720
GGCAAAGGAG CGTCCTTACT GAAGTACCTG GCAGGGGAGT TTTCAATCCC AGTTATCTTG      780
ACGAATCAAA TTACGACCCA TCTGAGTGGA GCCCTCCCTT CTCAAGCAGA CCTGGTGTCT      840
CCAGCTGATG ATTTGTCCCT GTCTGAAGGC ACTTCTGGAT CCAGCTGTTT GGTAGCTGCA      900
CTAGGAAACA CATGGGGTCA CTGTGTGAAC ACCCGGCTGA TTCTCCAGTA CCTTGATTCA      960
GAGAGAAGGC AGATTCTCAT TGCCAAGTCT CCTCTGGCTG CCTTCACCTC CTTTGTCTAC     1020
ACCATCAAGG GGAAGGCCT GGTCTTCAA GGCCACGAAA GACCATAGGG ATACTGTGAC     1080
CTTTGTCTAG TGCTGATTGC ATGTGACTCA TGAAATGAAA CAGGACTGCG CTGCTTGGAA     1140
AAAGGAAACG GAAGCCAACA TAATGAGGAT TAATTGGTTG GTTGCTGTTG AGGTGGTAAC     1200
AGTGATTTC AAGCCGGAAG GTGAAGATGA AGAAGCCTTT ATCCAGTCTC TGGATGCAGA     1260
GGCTAGGGGC TCCACCACCG TGGGATGTCA GCGGCCATCG TAATAATTG CACTTACACA     1320
AGCACCTTTC AGCCATGCCC CTCAAAGTGG TTCAGCCACA TTAATTAATT AAAGCCCACA     1380
ATCCCCCTAG GGAGAGCAGG AGGGGGACTA ACAAGATTG TAATTACAGA AGGGAAAATT     1440
TCCGAATAAA GTATTGTTCC GCCAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA     1500
AAAAAAAAAA AAAAAAAAAA AAAAAA                                     1525

```

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1699 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

CGACGGCCCCG GGCTGGTATT ATAGCAGGTA TCACTTGGTT TTCTACTGGG GGAAACAAGT      60
CATTGCTAAC AAATTCCCAT GGGAGAGAAA TGAGGAGGAT GTATTTTGT TTGTGAGAGG      120
TGTGTATGTA TGTATATTGT GTGTGCGTGT GTGTGTGTGT GAGAGAGAGA GATTGATTCA      180
GTCTGATTCA GAGAATTTAG GTGTTAAATA GAAATTTGGG CCATGGTATT GGAAATAAAC      240
AAATATATAC ATTCTCAGTA TACATATATT TTCATTCCAA AATGTTACTT CTTTTCTGAT      300
AACTATATTG CTTTATTCCC TTGGATCCAT GAAGAGTTCC TGTTCAGTT CGTTCAGAG      360
GATACTTCTT TACCATCTCA ATGAGATATA CAGCTTCTCC TTTGTATGCA TTAAGAGACT      420
CACAGTAATT CTTTTTTAGC TCTGTGAAGA TAAATCTTTC ATGAGCCTCA TTTACCCCTA      480
GCAAAGTACA ATAGTGAAAT TTAAGTGCAT GTGAGAATAT AAGCAGCTAG TGTAATAAAG      540
AACATTTTGG GCCAGGTCTG ATCGCTCATG CCTGTAATCC CAGCACTTTA GGAGGTCAAG      600
GCGAGAGGAT CACTTGAGCC CAGGAGTTCG AGACCAGCTT GGGCAACATG GCAAAACCCT      660
GTCTCTACAA AAAATACAAA AATTGGGCAG GCATGGTGTC GACCCAGTCT CTACAAAAAA      720
TACAAAAATT AGCCAGACAT GGTGGTGCAC GCTTGTGGTC CCAGCTACTT GGGAGGCTGA      780
GGTAGGAGGA TTGCTTGAGC CCAGGAGGGG GAGGTTGCAG TGAGCTGAGA TCGAGCCACT      840
GCACTCCAGC TGGGGTGACA GAGCCAGACC TGTCTCGCTC TCTCTCTCTC TCTATATATA      900
TATATTTAAA AAGAACATTT TAATACTGCA GTGATAAAAT CTCATTTGAT TCAGAAGGTG      960
TGCTCTGACT CCTAGAAAAA GGAAGAGTCA AATATGATTA TGGACTTGCA GTAGAGTGTA     1020
ATGGTTAAGA GGATAGGTTT CAGAATTAGA CTGCCTGGAT TCAAATTCTG GATCAGTTAT     1080
TTATGGTTTC TGGTGACAAT GGAAGAGTCA ACTTTCCAG GCTTTAGTTT TCTCATATGT     1140
AAAAAAGGGG CCAATAATCT ACTTTCCTTC TAGGGCTATT GAGAAGATTA AATGTGATAA     1200
TTTAGATAAG TTTTGAACA GTGCCTGGTA TGTGGTAGGT GCTCCATAAA TATACCTATT     1260
GCCGTTACAG TGCAATGTAA ATTGTTACAG TGCAATAGAC TTTCTAGTAG TTCTGTTTGG     1320
AAATATGCCT TGAAAGTTAA TTACATTTCC AAATAAAATT TATACATGCA TTGGAACATT     1380
TTAAGATGCT CTACAAATGT GAAGTGGTAC TATATTCATG TAGTAAATAT CAATTAATTG     1440
TGTGAAATTA TATTTGAGGT TGCCTTGTAG ATTTTCTATG TGCCTGTTTG ACGAACAATT     1500
GTCCCTCCTA TTTAAAACAT TTA AAAAGGT TCTATAGCAT TCCTTTATCA GTAATATTTT     1560
TAACACAATA TGTTTCATTT TGCATATGGA GAACTTGAG GAATTTTAA TTTTGTTTTG     1620
GATAGCCTAT TCACTATCAC TTATGTTATA TTCTGTTGTT TTTTTCATGG TTCTTCTTTT     1680
CTTTGCTGGA TCTGGAGGC

```

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2147 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TATCTCAGTA	GCACGTGCAC	ATAGCAACTA	CAATACCTGT	CACATAAATG	TAGTTACTTG	60
AATATATGTC	TCTTCATTCT	TCAATTGTAA	GTATGCAAAA	GGGAGGACAT	AAGCTTAGCA	120
TAGCATGTGC	TTAATATTGG	TGAAAGAAAC	AAATGAATAG	AGAATGTTAT	ATTTGGAGAG	180
TTTATATTAT	ATTTGGGAGA	GTAGGGAAAA	AACTTGAAGC	CATAAGCAGA	ATCGAGGGCA	240
AGTAGTGAGA	GTGGTACTGT	TAAATCAGAG	TGATTATTGC	TAAGGTCTTT	GTAATTTGGG	300
GTTGTAGGTG	TTTTTTGTTT	TTGTTGTTTG	AGGGTCTGAA	TTTATTCGTT	ATATGATGTT	360
ATTGCCTGGA	ACTACCTTAT	CTGAGAAGCA	GTAGGCAATA	GAGTAGCGTA	TAAATGTTGG	420
TAAATTTTCT	CTTAAGGAAA	CAAATTATCC	TTACAAAATT	CCAACTGAAA	GAAATAAAGA	480
GAATGTATCT	TGGTTTTGTG	TGGAGAGAGG	GAAGTAGAAG	ATGGGGGATG	AAGAGAGAGA	540
GGAGGGTTAT	TTATTGGGCT	ATATATAGTG	TTGGTAGTAG	GAATCTTAAT	TCTTGTGTGT	600
AGTTTTGTTC	TTTTGTGTAT	AGTTATTGAT	TATTACTTTA	TTCCATGGGA	ATAATGAGTT	660
CCTATTATTT	CTGGAGGATA	TTTTGCCATT	TCGATGAGAC	ACACAGCCTC	TTCTTTGCTA	720
TGCAATATTA	CGAGATTACA	ACAGTTCTAA	CTCCCTGAAG	ACAAATACTT	CATGAGTCTC	780
ATTAGCTATC	TAAGCTATAG	GAAGAGCAGA	ATTTAATTCT	ACATGGAAAC	AGTAAGAAGC	840
TAGTATAATG	AAGAATTTTA	TTGATATCAC	TTGATTGAAA	TTTGTCTCTG	CTCTTTAGAA	900
AAAGCAAGGG	TGAAATAAGA	TTTGTGATTC	TACAGTAGTA	ATGGGTAAGA	GGATAGGTCT	960
CAGGACAAAC	TGCCTAATGA	AACCCTAAAT	CTGTTATTTA	TTTATTTTCT	GATGACAGTG	1020
GGATAACTGA	CATTTACACA	TTAGCTTTCT	CATATGTAAA	AAAGAAATTT	TATTTTATT	1080
ATAGTCTGTC	AAGGAATATT	AAATATAAGG	TTTTGGAGCA	TGGTTGATAT	TTAGCAGATG	1140
TCTGTTTCATT	CTTGATCAGT	ATAGAGTTGC	CACTTGGAAA	ATGCATCTTG	AAGATTACAT	1200
AACCAGACAA	AATTTGTTAG	TAACACTCAG	TGGTCTTAAG	ATGTTATAAG	TGACGGGCTA	1260
GTCGTGGTAA	TCAACTTGAT	ACCTTGACCC	TCAGGAGAAG	AGGGATTGTC	TCCATCGGAT	1320
GGGCCTGTGA	GCATATCTGT	GGGGACGTTT	TTCTTGGACT	GCCTAGTTGA	TGGAAAAGGG	1380
CTTGGCTCAG	TGTCAGTGGT	CCTTCTTATG	GTGAGCAAGC	TGGGGGAAGC	GTTGCAGTAA	1440
GCAGTAGTCC	TTTGTGGTCT	CAGCTTCCTT	TTCTTCTCTC	TTCTTTCTTT	CTTTCTTTCT	1500
TTCTTTCTTT	CTTTCTTTCT	TTCTTCCTTC	CTTCCTTCCT	TTTCTCTCTT	TCTTTCTTTA	1560
GTTCCGTTTCG	TTTGTTCATT	CGTTCGTTTT	TCGAGACAGG	GTTTTTCTGT	ATAGCCCTGG	1620
CTGTCTTGGA	ACTCACTTTG	TAGACCAGGC	TGTCCTCGAA	CTCAGAAATC	CGCCTGCCTC	1680
TGCCTCCCTG	TGAGTGCTGG	AATTAAAGGC	ATGCGCCACC	CCGCCCCGGCT	TCTCAGCTTC	1740

CATTTCTGTT CAAGCTCTTG CCTTCAGCTC CTGCCTTGGC TTTCTGAGAC AAAGGCATAT	1800
AATCTGTAAG CCAAATCAAA CTTTTCTTCT CAACTTGCTT TTGGCCAGTG TTTTATTACA	1860
GCGACTAAAG GCAAAC TAGA CTACTATGTA AATGGGAAGC ACTGTAAAG TCAAGTAATA	1920
GCAAAAGATT ACATGGCCTG GATTTTTTGA GGTGCTTAC TTTCTCTGTG TACCCGGTTG	1980
TAAGTGTCTT TCCTACTTTT TTTATTAGCA TTTTTTTTCC ATGTTTGTCT TTGCACATAG	2040
AGAAGTTTGA AGCACTTTAT TTTGTAGGT GTTTTGTATA ATCTGTCCAC CATCATTTTT	2100
ATTGTTTTCT TATGTTTTTT CAAGATTCTT TTGGGAGCCC TGGAAAC	2147

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Gly Lys Thr Gln Met
 1 5

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CAGACGGTCA CACAGCTCTT GTGATAA

27

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ACCCACTCGT TTTAGTTTCT TGCTAC

26

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

TAGAGAGAGA GAGAGAGCGA GACAG

25

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

GTCGACCACG CGTGCCCTAT AG

22

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TCACTGCATC TGGAAGCAC

19

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

CTAACTAAAT GGCGAGCATT GAG

23

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 32 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAGCTCGAGG GTACCCATGG GTAGCAAGAA AC

32

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGAGGAAGCA GT

12

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CGAGGAAGAA AA

12

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGAGGCATTA AA

12

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GGTGGCGAAA TT

12

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: Other

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

CGTTACCCTA T

11

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

SGWGGMRRNA NA

12

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CGTT_CCCTA T

11

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCTA_CCCTA A

11

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CGTTACCCTA T

11

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

CGTTACCCAA T

11

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

CGGTTGCCAT G

11

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

CGTTACCCTA T

11

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

GTAGGTCGAA

10

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CGAGGAAGCA

10

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

CGAGGAAGAA

10

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CGTGGAGGCA

10

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

CGTGGTGGGA

10

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

CGAGGATGAC

10

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

CGTGGTTGAT

10

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

CGAGGTCGCA

10

(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

CTAGGTAGCA

10

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GTAGGTGTTA

10

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

CTAGGTAACA

10

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

CATGGTTGCC

10

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

CGWGGWNGMM

10

CLAIMS:

1. An isolated and purified nucleic acid that
 - a. encodes a protein comprising a sequence that is the sequence of a mammalian ATP-dependent homologous pairing protein or a protein substantially identical to the protein of SEQ ID NO: 1;
 - b. is labeled by random-primed hsREC2 cDNA in a Southern blot washed twice at 42°C for 20' in 2x SSC, 0.1% SDS followed by thrice at 50°C for 20'; and
 - c. contains a continuous coding sequence of at least 132 nucleotides of which greater than 100 are identical with a continuous 132 nucleotide sequence of SEQ ID NO: 2.
2. The nucleic acid of claim 1, which comprises a cDNA obtained from a species of mammal.
3. The nucleic acid of claim 1, which comprises a genomic DNA obtained from a species of mammal.
4. The nucleic acid of claim 3 which comprises the inserts of clones λ 5A and λ 1C, deposited as ATCC No. 97683 and No. 97682, respectively.
5. The nucleic acid of claim 3 that encodes a protein comprising the sequence of residues 2-350 of SEQ ID NO:1.
6. The nucleic acid of claim 1, in which the sequence of the pairing protein is greater than 90% identical to residues 4-347 of SEQ ID NO:1.
7. The nucleic acid of claim 6, which comprises the inserts of clones λ 5D2a and λ 7B1a, deposited as ATCC No. 97686 and No. 97684, respectively.
8. The nucleic acid of claim 6 that encodes a protein comprising a sequence that is

substantially identical to residues 4-347 of SEQ ID NO:1.

9. The nucleic acid of claim 5 having a sequence comprising the sequence of bp 74 to 1120 of SEQ ID NO:2.

10. The nucleic acid of claim 9, which further comprises a promoter.

11. The nucleic acid of claim 10, which is pcHsREC2 deposited as ATCC No. 97685.

12. A nucleic acid having a sequence which comprises a fragment of at least 20 nucleotides of SEQ ID NO:2 or SEQ ID NO:4 or a complement thereof and a label.

13. A kit comprising:

- a. a 5'-nucleic acid fragment having a sequence which comprises a 5'-sequence of at least 12 nucleotides of SEQ ID NO:2; and
- b. a 3'-nucleic acid fragment having a sequence which comprises a 3'-sequence of at least 12 nucleotides of the complement of SEQ ID NO: 2; wherein

the 3'-sequence is complementary to a portion of SEQ ID NO:2 that is 3' to the 5'-sequence.

14. A composition which comprises an ATPase, which composition is substantially free of other normally intracellular mammalian proteins, in which the sequence of the ATPase comprises a sequence that is substantially identical to a continuous sequence, at least 120 amino acids in length, of a mammalian ATP-dependent homologous pairing protein, and in which the ATPase is an ATP-dependent homologous pairing protein.

15. The composition of claim 14, in which the ATPase is an mREC2.

16. The composition of claim 14, which comprises an ATPase having a sequence which comprises at least 115 amino acids of SEQ ID NO:1 or which is substantially

identical thereto.

17. A composition which comprises an ATPase, which composition is substantially free of other normally intracellular mammalian proteins, in which the sequence of the ATPase comprises a sequence that is substantially identical to the sequence of residues 80-200 of SEQ ID NO:1, and in which the ATPase is an ATP-dependent homologous pairing protein.
18. The composition of claim 17, in which the ATPase is an mREC2.
19. The composition of claim 18, in which the ATPase is substantially identical to hsREC2.
20. The composition of claim 19, wherein the sequence of the ATPase comprises amino acids 2-350 of SEQ ID NO:1.
21. A method of classifying a sample of human tissue, which comprises:
 - a. quantifying the copies of *hsREC2* per diploid genome of a sample tissue; and
 - b. comparing the quantity of *hsREC2* per diploid genome of the sample tissue with the quantity of *hsREC2* per diploid genome of a standard tissue.
22. The method of claim 21 wherein the comparison is performed by measuring the lengths of microsatellite DNA at marker D14S258 and comparing the sizes present in the sample tissue and the sizes present in the standard tissue, provided the standard tissue and the sample tissue are from the same subject.
23. A method of classifying a sample of human tissue, which comprises comparing a *hsREC2* gene of a sample tissue with a *hsREC2* gene of a standard tissue.
24. The method of claim 23 wherein the comparison is performed by determining the

presence or absence of a single stranded conformational polymorphism between the *hsREC2* genes of the sample and of a standard tissue.

25. The method of claim 23 wherein the comparison is performed by obtaining the sequence of a fragment of the *hsREC2* of the sample tissue and comparing the obtained sequence with the sequence of SEQ ID NO:2 or or a complement thereof.
26. A transgenic mouse having at most one copy of *muREC2* per diploid genome that encodes a *muREC2* protein.
27. The transgenic mouse of claim 26 having no gene that encodes a *muREC2* protein.
28. A transgenic animal comprising an *mREC2* gene operably linked to a heterologous promoter such that the *mREC2* gene is expressed.
29. The transgenic animal of claim 28, in which the promoter is a tissue specific promoter or an inducible promoter.
30. An embryonic stem cell line comprising an *mREC2* gene operably linked to a heterologous promoter such that the *mREC2* gene is expressed.
31. The embryonic stem cell line of claim 30, in which the promoter is a tissue specific promoter or an inducible promoter.
32. An antibody or fragment thereof which binds a protein having a sequence of SEQ ID NO:1 and binds to no other human protein.
33. A method of making a specific genetic alteration in a mammalian cell which comprises:
 - a. increasing the level of *mREC2* in the cell; and
 - b. introducing into the cell a mutation-containing nucleic acid having

a region of homology with the genome of the cell,
such that the nucleic acid and the genome of the cell homologously recombine causing
the mutation in the genome.

34. The method of claim 33 wherein step (a) comprises transporting an exogenous nucleic acid that encodes a mREC2 into the cell.
35. The method of claim 33 wherein step (a) comprises transporting exogenous mREC2 protein into the cell.
36. The method of claim 33 wherein the mutation-containing nucleic acid is a CMutV.
37. A composition comprising an isolated and purified mammalian REC2 promoter.
38. The composition of claim 37, wherein the REC2 promoter is a radiation induceable promoter.
39. The composition of claim 37, wherein the REC2 promoter is operably linked to an enhancer.
40. The composition of claim 37, wherein the REC2 promoter is operably linked to a gene encoding a protein other than a mammalian Rec2 protein.
41. The composition of claim 37, wherein the REC2 promoter is operably linked to a gene encoding a Herpes Virus thymidine kinase gene.
42. The composition of claim 37, which further comprises a bacterial cloning plasmid that contains the REC2 promoter.
43. A composition comprising a mammalian, radiation induceable REC2 promoter operably linked to a strong enhancer.

44. The composition of claim 43, in which the composition further comprises a mammalian cell.
45. The composition of claim 43, in which the REC2 promoter is a hsREC2 promoter.
46. The composition of claim 43, wherein the enhancer is selected from the group consisting of the SV40 enhancer, the Hepatitis B Virus enhancer, the Cytomegalovirus enhancer and the α -fetoprotein enhancer,
47. The composition of claim 43, wherein the composition is a mammalian cell.

1/24

Met	Gly	Ser	Lys	Lys	Leu	Lys	Arg	Val	Gly	Leu	Ser	Gln	Glu	Leu	Cys
1				5					10					15	
Asp	Arg	Leu	Ser	Arg	His	Gln	Ile	Leu	Thr	Cys	Gln	Asp	Phe	Leu	Cys
		20						25					30		
Leu	Ser	Pro	Leu	Glu	Leu	Met	Lys	Val	Thr	Gly	Leu	Ser	Tyr	Arg	Gly
		35					40					45			
Val	His	Glu	Leu	Leu	Cys	Met	Val	Ser	Arg	Ala	Cys	Ala	Pro	Lys	Met
		50				55					60				
Gln	Thr	Ala	Tyr	Gly	Ile	Lys	Ala	Gln	Arg	Ser	Ala	Asp	Phe	Ser	Pro
65				70						75					80
Ala	Phe	Leu	Ser	Thr	Thr	Leu	Ser	Ala	Leu	Asp	Glu	Ala	Leu	His	Gly
				85					90					95	
Gly	Val	Ala	Cys	Gly	Ser	Leu	Thr	Glu	Ile	Thr	Gly	Pro	Pro	Gly	Cys
			100					105					110		
Gly	Lys	Thr	Gln	Phe	Cys	Ile	Met	Met	Ser	Ile	Leu	Ala	Thr	Leu	Pro
		115				120						125			
Thr	Asn	Met	Gly	Gly	Leu	Glu	Gly	Ala	Val	Val	Tyr	Ile	Asp	Thr	Glu
						135					140				
Ser	Ala	Phe	Ser	Ala	Glu	Arg	Leu	Val	Glu	Ile	Ala	Glu	Ser	Arg	Phe
145					150					155					160
Pro	Arg	Tyr	Phe	Asn	Thr	Glu	Glu	Lys	Leu	Leu	Thr	Ser	Ser	Ser	Lys
				165					170						175

FIG.1A

2/24

Val	His	Leu	Tyr	Arg	Glu	Leu	Thr	Cys	Asp	Glu	Val	Leu	Gln	Arg	Ile
			180					185					190		
Glu	Ser	Leu	Glu	Glu	Glu	Ile	Ile	Ser	Lys	Gly	Ile	Lys	Leu	Val	Ile
		195					200					205			
Leu	Asp	Ser	Val	Ala	Ser	Val	Val	Arg	Lys	Glu	Phe	Asp	Ala	Gln	Leu
	210					215					220				
Gln	Gly	Asn	Leu	Lys	Glu	Arg	Asn	Lys	Phe	Leu	Ala	Arg	Glu	Ala	Ser
225					230					235					240
Ser	Leu	Lys	Tyr	Leu	Ala	Glu	Glu	Phe	Ser	Ile	Pro	Val	Ile	Leu	Thr
				245					250					255	
Asn	Gln	Ile	Thr	Thr	His	Leu	Ser	Gly	Ala	Leu	Ala	Ser	Gln	Ala	Asp
			260					265					270		
Leu	Val	Ser	Pro	Ala	Asp	Asp	Leu	Ser	Leu	Ser	Glu	Gly	Thr	Ser	Gly
		275					280					285			
Ser	Ser	Cys	Val	Ile	Ala	Ala	Leu	Gly	Asn	Thr	Trp	Ser	His	Ser	Val
	290					295					300				
Asn	Thr	Arg	Leu	Ile	Leu	Gln	Tyr	Leu	Asp	Ser	Glu	Arg	Arg	Gln	Ile
305					310					315					320
Leu	Ile	Ala	Lys	Ser	Pro	Leu	Ala	Pro	Phe	Thr	Ser	Phe	Val	Tyr	Thr
				325					330					335	
Ile	Lys	Glu	Glu	Gly	Leu	Val	Leu	Gln	Ala	Tyr	Gly	Asn	Ser		
			340					345					350		

FIG.1B

3/24

CGGACGCGTG GCGCGGGGA AACTGTGTAA AGGTTGGGA AACTTGAAAG TTGGATGCTG 60
CAGACCCGGC ATGGGTAGCA AGAACTAAA ACGAGTGGT TTATCACAAAG AGCTGTGTGA 120
CCGTCTGAGT AGACATCAGA TCCTTACCTG TCAGGACTTT TTATGTCTTT CCCCACTGGA 180
GCTTATGAAG GTGACTGGTC TGAGTTATCG AGGTGTCCAT GAACCTCTAT GTATGGTCAG 240
CAGGGCCTGT GCCCAAGA TGCAACGGC TTATGGGATA AAAGCACAA GGTCTGCTGA 300
TTTCTCACCA GCATTCTTAT CTACTACCCT TTCTGCTTTG GACGAAGCCC TGCATGGTGG 360
TGTGGCTTGT GGATCCCTCA CAGAGATTAC AGGTCCACCA GGTGTGGAA AAACTCAGTT 420
TTGTATAATG ATGAGCATTT TGGCTACATT ACCCACCAAC ATGGGAGGAT TAGAAGGAGC 480
TGTGGGTGAC ATTGACACAG AGTCTGCATT TAGTGCTGAA AGACTGGTTG AAATAGCAGA 540
ATCCCGTTTT CCCAGATATT TTAACACTGA AGAAAGTTA CTTTGTGACAA GTAGTAAAGT 600
TCATCTTTAT CGGGAACCTCA CCTGTGATGA AGTTCTACAA AGGATTGAAT CTTTGAAGA 660
AGAAATTATC TCAAAAGGAA TTAAACTTGT GATTCTTGAC TCTGTTGCTT CTGTGGTCAG 720
AAAGGAGTTT GATGCACAAC TTCAAGGCCAA TCTCAAGAA AGAAACAAGT TCTTGGCAAG 780
AGAGGCATCC TCCTTGAAGT ATTTGGCTGA GGAGTTTCA ATCCCAGTTA TCTTGACGAA 840
TCAGATTACA ACCCATCTGA GTGGAGCCCT GGCTTCTCAG GCAGACCTGG TGTCTCCAGC 900

FIG.1C

4/24

TGATGATTG	TCCCTGTCTG	AAGGCACCTC	TGGATCCAGC	TGTGTGATAG	CCGCAC TAGG	960
AAATACCTGG	AGTCACAGTG	TGAATACCCG	GCTGATCCTC	CAGTACCTTG	ATTCAGAGAG	1020
AAGACAGATT	CTTATTGCCA	AGTCCCCCTCT	GGCTCCCCTTC	ACCTCATTTG	TCTACACCAT	1080
CAAGGAGGAA	GGCCTGGTTC	TTCAAGCCTA	TGGAAATTCC	TAGAGACAGA	TAAATGTGCA	1140
AACCTGTTCA	TCTTGCCCAAG	AAAATCCGC	TTTTCTGCCA	CAGAAACAAA	ATATTGGGAA	1200
AGAGTCTTGT	GGTGAAACAC	CCATCGTTCT	CTGCTAAAC	ATTGGTTGC	TACTGTGTAG	1260
ACTCAGCTTA	AGTCATGGAA	TTCTAGAGGA	TGTATCTCAC	AAGTAGGATC	AAGAACAAGC	1320
CCAACAGTAA	TCTGCATCAT	AAGCTGATTT	GATACCATGG	CACTGACAAAT	GGGCAC TGAT	1380
TTGATACCAT	GGCACTGACA	ATGGGCACAC	AGGGAACAGG	AAATGGGAAT	GAGAGCAAGG	1440
GTTGGGTTGT	GTTCTGTGGAA	CACATAGGTT	TTTTTTTTTA	ACTTCTCTCT	TCTAAAATAT	1500
TTCATTTTGA	TGGAGGTGAA	ATTTATATAA	GATGAAATTA	ACCATTTTAA	AGTAAACAAT	1560
TCCGTGGCAA	CTAGATATCA	TGATGTGCAA	CCAGCATCTC	TGCTAGTTC	CCAAATATTT	1620
CATCACCCCC	AAAAGCAAGA	CCCATAACCA	TTATGCAAGT	GTTCCCTATTT	CCCCCTCCTC	1680
CCAGCTCCTG	GGAAACCACC	AATCTACTTT	TTTTCTATGG	CTTTACCTAA	TCTGGAAATT	1740
TCAAATAAAT	GGGATCAAAT	AGTTTCCCAA	AAAAAATAAA	AAAAAATAAA	AAAAAA	1797

FIG.1D

5/24

Met	Ser	Ser	Lys	Lys	Leu	Arg	Arg	Val	Gly	Leu	Ser	Pro	Glu	Leu	Cys
1			5						10					15	
Asp	Arg	Leu	Ser	Arg	Tyr	Leu	Ile	Val	Asn	Cys	Gln	His	Phe	Leu	Ser
			20					25					30		
Leu	Ser	Pro	Leu	Glu	Leu	Met	Lys	Val	Thr	Gly	Leu	Ser	Tyr	Arg	Gly
		35					40					45			
Val	His	Glu	Leu	Leu	His	Thr	Val	Ser	Lys	Ala	Cys	Ala	Pro	Gln	Met
						55					60				
Gln	Thr	Ala	Tyr	Glu	Leu	Lys	Thr	Arg	Arg	Ser	Ala	His	Leu	Ser	Pro
65					70					75					80
Ala	Phe	Leu	Ser	Thr	Thr	Leu	Cys	Ala	Leu	Asp	Glu	Ala	Leu	His	Gly
				85					90					95	
Gly	Val	Pro	Cys	Gly	Ser	Leu	Thr	Glu	Ile	Thr	Gly	Pro	Pro	Gly	Cys
			100					105					110		
Gly	Lys	Thr	Gln	Phe	Cys	Ile	Met	Met	Ser	Val	Leu	Ala	Thr	Leu	Pro
		115				120						125			
Thr	Ser	Leu	Gly	Gly	Leu	Glu	Gly	Ala	Val	Val	Tyr	Ile	Asp	Thr	Glu
					135						140				
Ser	Ala	Phe	Thr	Ala	Glu	Arg	Leu	Val	Glu	Ile	Ala	Glu	Ser	Arg	Phe
145					150					155					160
Pro	Gln	Tyr	Phe	Asn	Thr	Glu	Glu	Lys	Leu	Leu	Thr	Ser	Ser	Ser	Arg
				165					170						175

FIG.1E

6/24

Val	His	Leu	Cys	Arg	Glu	Leu	Thr	Cys	Glu	Gly	Leu	Gln	Arg	Leu
			180					185				190		
Glu	Ser	Leu	Glu	Glu	Glu	Ile	Ile	Ser	Lys	Gly	Val	Lys	Leu	Ile
		195					200					205		
Val	Asp	Ser	Ile	Ala	Ser	Val	Val	Arg	Lys	Glu	Phe	Asp	Pro	Lys
	210					215					220			
Gln	Gly	Asn	Ile	Lys	Glu	Arg	Asn	Lys	Phe	Leu	Gly	Lys	Gly	Ala
225					230					235				Ser
Leu	Leu	Lys	Tyr	Leu	Ala	Gly	Glu	Phe	Ser	Ile	Pro	Val	Ile	Leu
				245					250					Thr
Asn	Gln	Ile	Thr	Thr	His	Leu	Ser	Gly	Ala	Leu	Pro	Ser	Gln	Ala
			260					265					270	Asp
Leu	Val	Ser	Pro	Ala	Asp	Asp	Leu	Ser	Leu	Ser	Glu	Gly	Thr	Ser
		275					280							Gly
Ser	Ser	Cys	Leu	Val	Ala	Ala	Leu	Gly	Asn	Thr	Trp	Gly	His	Cys
	290					295					300			Val
Asn	Thr	Arg	Leu	Ile	Leu	Gln	Tyr	Leu	Asp	Ser	Glu	Arg	Arg	Gln
305					310					315				Ile
Leu	Ile	Ala	Lys	Ser	Pro	Leu	Ala	Ala	Phe	Thr	Ser	Phe	Val	Tyr
				325					330					Thr
Ile	Lys	Gly	Glu	Gly	Leu	Val	Leu	Gln	Gly	His	Glu	Arg	Pro	
			340					345					350	

FIG.1F

7/24

60 GGGAGCCCTG GAAACATGAG CAGCAAGAAA CTAAGACGAG TGGGTTTATC TCCAGAGCTG
 120 TGTGACCGTT TAAGCAGATA CCGTATTGTT AACTGTCAGC ACTTTTAAAG TCTCTCCCCA
 180 CTAGAACTTA TGAAAGTGAC TGGCCTGAGT TACAGAGGTG TCCACGAGT TCTTCATACA
 240 GTAAGCAAGG CCTGTGCCCC CACCGGCATT TCTCACAGAG ACAGGCTTATG AGTTAAAGAC ACGAAGGTCT
 300 GCACATCTCT CTTGTGGATC TAATGATGAG TGCTTTAGCT ACATTACCTA ACCCTGTGCG CTTGGATGA AGCATTGCAC
 360 GGTGGTGTGC CAGTTTGTGA TCTACATCGA TCTTCCACA ATATTTAAC ACTGAGGAAA GAGGGCTTC ATTGCTTCT CACAGCTGGG
 420 GGGGCTGTGG GCGGAATCTC GTTTTCCACA TTTGCCGAGA TCTATTGCGA AGGAGTTAAG GAGGGCTTC TACAAAGCT TCGACTCCAT
 480 AGAGTTCATC GAGGAAGAGA TCATTTCGAA AGTTTGACCC AGTTCCTTACT TACGACCCA TTTGTGCTG TTTGACTCCAT TCGACTCCAT
 540 GAGGAAGAGA GTCAGAAAGG CGTCCCTTACT TACGACCCA TTTGTGCTG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 600 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 660 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 720 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 780 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 840 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 900 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 960 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1020 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1080 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1140 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1200 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1260 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1320 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1380 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1440 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1500 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT
 1525 GTCAGAAAGG ACGAATCAAA TTAGCTGATG TTTGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT TCGACTCCAT

FIG.1G

8/24

MSGKKLKRUGLSQELCDRLSAHQILTCQDFLCSPLELMKUTGLS
 NLS
 YRGVHELLCMUSRACAPKMQTAYGIKAQRSADFSPAFLSTLSA
 50
 LDEALHGGVACGSLTEITGPPGCGKIQFCIMMSILATLPTNMGGL
 100 A BOX
 EGADVYIDTESAFSAERLVEIAESAPRYFNTTEKLLLTSSKUHLY
 150 P
 BELTCDEVLORIESLEEEIISKGIKLWILDSUASDUARKEFDAQLQG
 DNA 200 B BOX
 NLKERNKFLAREASSLKYLAEESIPUILTNQITTHLSGALASQAD
 250
 LUSPADDLSEGTSGSSCVIARALGNTWWSHUNTALILQYLDSEAA
 300
 QILIAKSPAPFTSFUYTIKEEGLULQAYGNS*
 350

FIG.2A

9/24




FIG.2B

10/24

U.m. 124 LNDARFASSCIVPPTQGYDGNFPGAQCFVYDS DAGSDSDARSSIDAVMHE 173
 Human 1 MGSKKLKR...VGLSQELCDRLSRHQILTCQDFLCLSPLELMKVTGLSYR 47
 174 DI.ELPSTFCRPQTPQTHDVARDEHHDGYL CDPKVDHASVARDVLSLGRQ 222
 48 GVHEL LCMVSR...CAPKMQTAYGIKAQRSADFS 79
 223 RHVFS SGRRELDLLGGGVRSAVLTEL VGESGSGKTQMAIQVCTYAALGL 272
 80 PAF LSTT LSA LDEALHGGVACGSLTEITGPPGCGKTQFCIMMSILATL... 127
 273 VPLSQADDHDKGNNTFQSRTFVRDPIHASTKDDTLSDILQSYGMEPSIGS 322
 128PTNMGLEG..... 136
 323 HRGMGACYITSGGERAAHSIVNRALELASFAINERFDRVYPVCDPTQSSQ 372
 137AVVYIDTESAFSAERLVEIA.....ESRFP RYF..... 164
 373 DADGRRDALLAKAQQLGRRQALANLHIA CVADVEALEHALKYSLPGLIRR 422
 165 ...NTEEKLLLTSSKVHLYRELTCDDEV..LQRIESLEEEI..... 199

FIG.2C

11/24

```

423 LWSSKRQSGVSREIGVVVDNLPALFQQDQAAASDIDSLFQRSKMLVEIA 472
    :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::|
200 .....ISKGIKLVILDSVASVRKEFDAQLQ.GNLKERNKFLAREA 239

473 DALKRISAVQWRGASDCGSSAGRAVLVLNHHVSDAFGIDKQIARRFVFDSA 522
    ..||
240 SSLK.....YLAEEFSIPVILTNQITTHL..... 263

573 SGLLASIAPT LAEAVGARELDSACASNDVPLRLEARTAQLGQTWSNLIN 622
    ||||| :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::|
264 SGALASQADLVSPADDLSLSEGTSGSSCV.....IAALGNTWSHSHSVN 305

623 VRVFL....SKTRARICMRDDQAPACEPVRQNTNQRTASKSLMNTVRKA 668
    :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::|
306 TRLILQYLDSERRQILIAKSPLAP.....FTSFVYTIKEE 340

669 AVVINPFGAT 678
    :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::| :|::|
341 GLVLQAYGNS 350

```

FIG.2D

12/24




FIG.3

13/24




FIG.4

14/24

SC1 + pcDNA
SC1 + pcCAT
SC1 + pchREC2

HREC2 Enhanced Conversion vs Controls




FIG.5A

16/24




FIG.6

17/24

1 CGACGGCCCG GGCTGGTATT ATAGCAGGTA TCACTTGGTT TTCTACTGGG
 51 GGAAACAAGT CATTGCTAAC AAATTCCCAT GGGAGAGAAA TGAGGAGGAT
 101 GTATTTTGT TTGTGAGAGG TGTGTAIGTA TGTATATTGT GTGTGCGTGT
 151 GTGTGTGTGT GAGAGAGAGA GATTGATTCA GTCTGATTCA GAGAAATTAG RHP51-URS
 201 GTGTTAAATA GAAATTGGG CCATGGTATT GGAAATAAAC AAATATATAC
 251 ATTCTCAGTA TACATATATT TTCATTCCAA AATGTTACTT CTTTTCTGAT
 301 AACTATATTG CTTTATTCCC TTGGATCCAT GAAGAGTTCC TGTTCAGTT
 351 CGTTCAGAG GATACTTCTT TACCATCTCA ATGAGATATA CAGCTTCTCC
 401 TTTGTATGCA TTAAGAGACT CACAGTAATT CTTTTTAGC TCTGTGAAGA
 451 TAAATCTTTC ATGAGCCTCA TTTACCCCTA GCAAAGTACA ATAGTGAAT
 501 TTAAGTGCAT GTGAGAATAT AAGCAGCTAG TGTAAATAAG AACATTTTGG
 551 GCCAGGTCTG ATCGCTCATG CCTGTAATCC CAGCACTTA GGAGGTCAAG
 601 GCGAGAGGAT CACTTGAGCC CAGGAGTTCC AGACCAGCTT GGGCAACATG
 651 GCAAACCCCT GTCTCTACAA AAATACAAA AATTGGGCAG GCATGGTGTC

<URS>

PHR1-URS

RAD23

RAD16-URS

FIG. 7A

FIG. 7B

SUBSTITUTE SHEET (RULE 26)

19/24

1451 TATTGAGGT TGCCTTGTAG ATTTCTATG TGCCTGTTG ACGAACAAAT
RNR3-UAS

1501 GTCCCTCCTA TTTAAACAT TTAAAAAGGT TCTATAGCAT TCCTTTATCA

1551 GTAATATTT TAACACAATA TGTTTCATTT TGCATATGGA GAAACTTGAG
RAD23-UAS

1601 GAATTTTAA TTTTGTTTG GATAGCCTAT TCACTATCAC TTATGTTATA
PHR1-URS RAD51-UAS RHP51-UAS TATA BOX
RNR3-UAS

1651 TTCTGTTGTT TTTTTCATGG TTCTTCTTTT CTTTGCTGGA TCTGGAGGC
<PHR1-UAS> (OVERLAP WITH DRE2)

20/24

1 TATCTCAGTA GCACGTGCAC ATAGCAACTA CAATACCTGT CACATAAATG
 RNR3
 51 TAGTTACTTG AATATATGTC TCTTCATTCT TCAATTGTAA GTATGCCAAA
 RAD23
 101 GGGAGGACAT AAGCTTAGCA TAGCATGTGC TTAATATTGG TGAAAGAAAC <RAD6>
 151 AAATGAATAG AGAATGTTAT ATTTGGAGAG TTTATATTAT ATTTGGGAGA
 201 GTAGGGAAA AACTTGAAGC CATAAGCAGA ATCGAGGGCA AGTAGTGAGA
 251 GTGGTACTGT TAAATCAGAG TGATTATTGC TAAGGTCTTT GTAATTGGG
 301 GTTGTAGGTG TTTTTTGTTT TTGTTGTTTG AGGGTCTGAA TTTATTTCGTT
 RHP51 RNR3
 351 ATATGATGTT ATTGCCTGGA ACTACCTTAT CTGAGAAGCA GTAGGCAATA
 RAD51-UAS
 401 GAGTAGCGTA TAAATGTTGG TAAATTTTCT CTTAAGGAAA CAAATTATCC
 RAD7
 451 TIACAAAATT CCAACTGAAA GAAATAAAGA GAATGTATCT TGGTTTGTG
 RAD54-UAS
 501 TGGAGAGAGG GAAGTAGAAG ATGGGGGATG AAGAGAGAGA GGAGGGTTAT
 RAD-1
 551 TTATTGGGCT ATATATAGTG TTGGTAGTAG GAATCTTAAT TCTTGTGTGT
 601 AGTTTGTTC TTTTGTGTAT AGTTATTGAT TATTACTTTA TTCCATGGGA
 651 ATAATGAGTT CCTATTATTT CTGGAGGATA TTTTGCCATT TCGATGAGAC
 701 ACACAGCCTC TTCTTTGCTA TGCAATATTA CGAGATTACA ACAGTTCTAA

FIG.7D

FIG. 7E

SUBSTITUTE SHEET (RULE 26)

1501 TTCTTTCTTT CTTTCTTTCT TTCTTCCTTC CTTCCTTCCT TTTCTCTCTT
RHP51-UAS

1551 TCTTTCTTTA GTTCCGTTTCG TTTGTTTCATT CGTTCGTTTT TCGAGACAGG
RHP51-UAS

1601 GTTTTCTGT ATAGCCCTGG CTGTCCCTGGA ACTCACTTTG TAGACCAGGC
<UAS>

1651 TGTCCCTCGAA CTCAGAAATC CGCCTGCCTC TGCCTCCCTG TGAGTGCTGG RAD2-UAS

1701 AATTAAAGGC ATGCGCCACC CCGCCCGGCT TCTCAGCTTC CATTCTCTGT

1751 CAAGCTCTTG CCTTCAGCTC CTGCCCTGGC TTTCTGAGAC AAAGGCATAT

1801 AATCTGTAAG CCAATCAAA CTTTCTTCT CAACTTGCTT TTGGCCAGTG

1851 TTTTATTACA GCGACTAAAG GCAAACTAGA CTACTATGTA AATGGGAAGC PHR1
RHP51-2

1901 ACTGTTAAAG TCAAGTAATA GCAAAAGATT ACATGGCCTG GATTTTTTGA
RNR2

1951 GGTIGCTTAC TTTCTCTGTG TA'CCCGGTG TAAGTGCTT TCCTACTTTT
RPH51-UAS

2001 TTTATTAGCA TTTTTTTTCC ATGTTTGCT TTGCACATAG AGAAGTTTGA
<DRS>

2051 AGCACTTTAT TTTGTAGGT GTTTTGATA ATCTGTCCAC CATCATTTTT

2101 ATTGTTTCT TATGTTTTTT CAAGATTCT TTGGAGCCC TGGAAAC

FIG. 7F

23/24

FIG.8A




FIG.8B




FIG.8C




FIG.8D




FIG.8E




FIG.8F




FIG.8G





FIG.8H



INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01217

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/12, 15/87; C12P 19/34

US CL : 435/172.3; 536/23.5, 24.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/172.3; 536/23.5, 24.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Computer Search - STN and APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KMIEC, E. C. et al. The <i>REC2</i> Gene Encodes The Homologous Pairing Protein Of <i>Ustilago maydis</i> . Mol. Cell. Biol. November 1994, Vol. 14, No. 11, pages 7163-7172.	1-13, 33-47
A, P	FAN, G. et al. A Novel Link Between <i>REC2</i> , a DNA Recombinase, the Retinoblastoma Protein, and Apoptosis. J. Biol. Chem. 01 August 1997, Vol. 272, No. 31, pages 19413-19417.	1-13, 33-47
X, P	RICE, M. C. et al. Isolation Of Human And Mouse Genes Based On Homology To <i>REC2</i> , A Recombinational Repair Gene From the fungus <i>Ustilago maydis</i> . Proc. Natl. Acad. Sci. USA. 08 July 1997, Vol. 94, No. 14, pages 7417-7422, see entire document.	1-13, 33-47

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance		
"E" earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search

04 DECEMBER 1997

Date of mailing of the international search report

06 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

CHARLES PATTERSON

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01217

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	KARUDAPURAM, S. et al. <i>The Haemophilus influenzae dprABC</i> Genes Constitute A Competence-Inducible Operon That Requires The Product Of The <i>ifoX(sxy)</i> Gene For Transcriptional Activation. J. Bacteriol. August 1997, Vol. 179, No. 15, pages 4815-4820, see entire document.	37-47

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01217

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-13 & 33-47
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☒ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-13, drawn to a nucleic acid and a kit comprising part of the nucleic acid.

Group II, claims 14-20, drawn to an ATPase enzyme.

Group III, claim(s) 21-25, drawn to a method of classifying a sample of human tissue.

Group IV, claims 26-27, drawn to a transgenic mouse having *muREC2*.

Group V, claims 28-31, drawn to a transgenic animal having the *mREC2* gene and a cell line containing the gene.

Group VI, claim 32, drawn to an antibody.

Group VII, claims 33-36, drawn to a method of making a specific genetic alteration in a mammalian cell.

Group VIII, claims 37-47, drawn to a *REC2* promoter.

The inventions listed as Groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I, II, IV, V, VI and VIII are drawn to completely different and distinct products which do not share a special technical feature. Group III is a different method of use of the product of Group I and this product could be used in a materially different process such as in the kit of Group I. Groups VII and VIII are completely different processes using different products from the other groups which do not share a special technical feature.